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CHAPTER 1: INTRODUCTION 
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Endometrial Cancer 
In the United States, endometrial cancer is the leading cancer of the female 
reproductive tract. There are 40,100 new cases and 7,470 deaths from endometrial cancer 
estimated for 2008 (47). The average five year survival rate for endometrial cancer is 84% 
however, this figure is substantially lower in patients diagnosed with late stage, advanced 
disease and much higher for patients diagnosed in early stage disease (47). Endometrial 
cancer (EC) has been associated with several risk factors including obesity, diabetes, 
hypertension, previously documented occurrence of hereditary non-polyposis colorectal 
cancer (HNPCC), and heightened exposure to estrogen (25).  As of yet, there has not been a 
dependable molecular predictor of endometrial cancer occurrence in women with these 
predisposing factors. The goal of our lab is to identify genes that are aberrantly expressed in 
EC and may serve as molecular biomarkers of EC progression. One candidate protein that 
we are exploring as a biomarker of EC progression is the cell survival protein survivin.  
 
Survivin 
Discovery 
 Survivin (BIRC5) was first cloned and characterized in Diego Altieri’s laboratory at 
Yale University School of Medicine in 1997.  At the time, the Altieri laboratory was 
studying components of the coagulation cascade and their contribution to vascular injury. 
Specifically, they were interested in the mechanism by which activation of the coagulation 
cascade through protease factor Xa binding to its receptor effector cell protease-1 (EPR-1) 
not only promoted thrombin formation but also promoted cellular growth (2, 5, 87). To 
identify other genes homologous to EPR-1, they conducted hybridization screening of the 
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human P1 genomic library with the cDNA of EPR-1 and found a new gene in the same locus 
but on the DNA strand opposite of EPR-1 (Figure 1).  
 
 
 
 
 
 
 
 
 
 
Sequence analysis of this new gene predicted the formation of a unique 1.9kb transcript that 
would form a 142 amino acid protein, unrelated to EPR-1, with a molecular weight of 
16,389kD that were later identified in transformed lymphoid cell lines by Northern blotting 
and immunoblotting. Blast analysis of the protein sequence indicated the presence of a 
baculovirus IAP repeat (BIR) domain that is the distinguishing feature of the IAP inhibitor 
of apoptosis family, thus the new protein was presumed to function as a survival protein and 
was named survivin (6).     
 
Structure 
 The 14,796 nucleotide survivin gene is located on chromosome 17q25, 
contains a TATA-less proximal promoter,  4 dominant exons (1,2,3,4), 2 cryptic exons 
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Figure 1: Map of the survivin gene 
The survivin and EPR-1 genes are located on opposite strands at the chromosome 
17q25 locus. Arrows indicate the direction of transcription, numbered boxes 
represent exons, gray shading indicates the UTR.  
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(2B,3B) that are introduced by alternative splicing events and 3 introns. Five survivin 
transcripts have been identified which code for functional proteins (Figure 2). The 
predominant survivin transcript is made up of all four exons and encodes a 142 amino acid 
(aa) protein. It contains the BIR domain, and a carboxy-terminal coiled-coil (microtubule 
interacting) domain that directs survivin interaction with tubulin (6, 9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The BIR and coiled-coil domains in the survivin protein are separated by the dimer 
interface. The survivin2B transcript includes a 69-bp cryptic exon 2B from intron 2 and 
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Name    Protein size      Function
Survivin          142aa           survival
Survivin2b      165aa          apoptosis
Survivin∆eX3 137aa           survival
Survivin3b       120aa           survival
Survivin2α 74aa           apoptosis
 
Figure 2: Schematic of Survivin Splice Variants 
The survivin gene encodes for the primary survivin transcript as well as four splice 
variants. Survivin2B and survivin2α retain portions of intron2 while survivin3B retains 
part of intron3 and survivin∆eX3 is missing all of exon3. Horizontal bars indicate the 
BIR domain, vertical lines mark a truncated BIR domain, dashed lines indicate the 
coiled coil domain, an X indicates an in-frame stop signal and the blue asterisk indicates 
a unique nuclear localization signal.  
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encodes a 165aa protein with a truncated BIR domain and an intact coiled-coil domain. The 
survivin∆eX3 transcript is missing all of exon3 resulting in a frame shift which incorporates 
part of the downstream 3’ un-translated region (UTR) into the transcript. This variant 
encodes for a 137aa protein with a truncated BIR domain, a coiled-coil domain and a unique 
nuclear localization signal (NLS) which is homologous to the NLS found in steroid hormone 
receptors (66).  Survivin2α includes a 197-bp insertion from intron 2 which creates a 
premature stop codon within the insertion. The resultant 74aa protein has a truncated BIR 
domain, and lacks the coiled-coil domain (12). Survivin3B includes a 165-bp cryptic exon 
3B from intron 3 and encodes a 120aa protein that has been associated with increased 
cytoprotection (9, 53). The survivin∆eX3 protein retains the pro-survival function of the 
primary survivin protein however, the survivin2B and survivin2α proteins have a dominant 
negative effect and actually promote cell death (13, 78). Most studies are focused on the 
dominant survivin isoform as its expression is much higher than the splice variant isoforms 
and we will focus our discussion on just the dominant survivin protein isoform. 
 
Function 
Studies of survivin function over the last 12 years have yielded varied and 
controversial results. The presence of the BIR domain makes survivin the smallest member 
of the IAP gene family and suggests that this protein functions to inhibit apoptosis. This is 
supported by evidence that survivin overexpression in various mammalian cells leads to 
enhanced cell survival by inhibition of apoptosis whereas survivin depletion leads to vast 
and spontaneous apoptosis (4). This function of survivin was initially debated because the 
survivin protein lacks the CARD (caspase activation and recruitment domain) domain 
6 
present in other IAPs and there was no evidence that survivin could directly bind and inhibit 
caspase activation. This was resolved as later studies indicated that the only IAP family 
member that is capable of direct caspase inactivation is the largest family member, XIAP, 
thus the inability of survivin to directly inhibit caspases did not negate its potential role as an 
IAP (23, 24). However, survivin knockdown in worms did not indicate any deficiencies in 
apoptosis, instead the phenotype indicated defective mitosis. Similarly, survivin knockout 
mice are embryonic lethal due to improper microtubule formation and polyploidy (104). 
Subsequent studies show that survivin functions both in apoptosis and cell cycle regulation 
according to its subcellular localization (3).  
 
Subcellular localization 
Recent studies indicate that there are distinct “pools” of survivin. These pools of 
survivin represent the dominant survivin protein and are distinct from the splice variants. 
One pool of survivin functions in normal cells during cell division and localizes to several 
parts of the mitotic machinery as part of the chromosomal passenger complex made up of 
Aurora B kinase, Inner centromere protein (INCENP) and Borealin. Aurora B kinase 
phosphorylation of survivin at Thr117 alters survivin localization at the centromere to 
maintain proper chromosome alignment and segregation (31, 62), bipolar spindle formation 
(88), and completion of cytokinesis (104). While these survivin functions promote the 
fidelity of cell division, during chromosome alignment, the occurrence of a disattached 
kinetochore activates checkpoint proteins to arrest division and the cell is subsequently 
marked for apoptosis. Here survivin, when phosphorylated by CDC2/cyclin B1 at Thr34, 
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exhibits increased protein stability, associates with the kinetochore microtubule, stabilizes it 
and indirectly inhibits caspase activation thereby evading apoptosis (31, 71, 77).  
 
A second pool of survivin localizes to the mitochondrial intermembrane space and 
mitochondrial matrix (21) and is associated with inhibition of apoptosis. Inside the 
mitochondria survivin is able to bind and sequester Smac (94), an XIAP inhibitor, 
preventing its release into the cytosol thus relieving XIAP from inhibition (15).  Certain cell 
death stimuli can, through a mechanism that has not been elucidated, stimulate the release of 
survivin into the cytosol where it forms a complex with XIAP, stabilizes it against 
proteasomal degradation, and further enhances cell survival through caspase inhibition (20).  
 
A third less understood pool of survivin exists in the nuclei of interphase cells 
especially in cancer cells. The function of survivin in the nuclei of interphase cells has not 
been elucidated but this population of survivin protein does not exhibit anti-apoptotic 
function (18) and is exported from the nucleus through an interaction with the Ran-GTP 
effector molecule Crm-1(54). X-ray crystallography indicates that the region of survivin that 
binds Crm-1overlaps the binding region of Borealin in the chromosomal passenger complex 
(49). This suggests that Crm-1 binding may prevent survivin from joining this complex.   
 
Expression 
Survivin’s pattern of expression is also distinct from the other IAPs. Survivin is 
highly expressed during embryonic and fetal development and is overexpressed in virtually 
all tumor types (6, 60, 78). In contrast, survivin is transcriptionally silent in most highly 
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differentiated adult tissues. It is however, expressed in the normal brain, ovary and in the 
proliferative phase of the cycling human endometrium (33, 55) suggesting that it may play a 
role in normal endometrial physiology. Many groups have implicated a physiological role 
for survivin in the murine endometrium but the precise function of survivin in this tissue is 
unclear. High expression of survivin has been found in the endometrium of mice exhibiting 
defective implantation and subsequent pregnancy loss (35, 61). Loss of survivin expression 
has also been described in the decidua of interleukin 11 receptor alpha null mice which are 
infertile due to aberrations in decidualization and trophoblast invasion (35).  
 
Transcriptional Regulation 
Survivin contains a TATA-less promoter such that transcription is driven through 
two critical Sp1 sites at the -151 and -171 positions (Figure 3) (6, 7, 60).  Survivin 
expression is tightly cell-cycle regulated through the several cell cycle dependent elements 
(CDE) and cycle homology regions (CHR) present in the survivin promoter that rapidly 
increase survivin expression during mitosis. Non-cell cycle mediated regulation of survivin 
has been observed in response to growth factor signaling (106), stimulation with hormones 
(30, 32, 72, 89) and cytokines (8). The survivin promoter also contains a validated p53 
binding site that overlaps an E2F binding site that binds p53 and several E2F family 
members (50, 82).   
 
 
 
 
Survivin Promoter EXON 1UTR
Sp1 site
CDE/CHR site
p53/E2F site
CpG island  
9 
 
 
 
 
  
 
The survivin promoter is GC rich with a characteristic CpG island. The observed 
frequency of the dinucleotide CG throughout the human genome is much lower than the 
mathematically expected frequency except in regions called CpG islands where there tends 
to be CG enrichment. The “p” in CpG refers to the phosphodiester bond linking the cytosine 
and guanine. The definition of a CpG island is a genomic region of greater than 200bp with 
a GC content greater than 50% and an observed/expected CpG ratio of 0.6 (36). The CpG 
island in the survivin promoter is 498bp in length with 51 CpG dinucleotides, 71% GC 
content and an observed/expected CpG ratio of 0.81(UCSC Genome Browser).  This 
characteristic CpG island extends into exon 1 (Figure 3) and has been shown to be subject to 
epigenetic regulation during development and in response to DNA damage (6, 7, 28, 40, 60).    
 
Epigenetics 
Epigenetics is the study of heritable changes which affect gene expression but do not 
cause genotypic changes. This form of gene regulation involves reversibly changing the 
structure of chromatin surrounding coding regions of DNA such that gene promoters 
become physically permissive or inhibitory to transcriptional activation.  Two well 
described types of epigenetic regulation are DNA methylation and histone tail modification. 
Figure 3: Map of the survivin promoter 
Representation of the proximal survivin promoter with blue circles indicating the Sp1 
sites, purple rectangles indicating the cell cycle regulation sites, yellow rectangle 
indicates the p53/E2F binding site and a gray rectangle indicates the CpG island.   
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The most common histone modifications are acetylation and de-acetylation of their amino 
terminal tails. Acetylation of the histone tails “opens up” the DNA allowing for recruitment 
of transcriptional machinery. Conversely, de-acetylation promotes tighter chromatin 
packaging and leaves the region repressive to transcriptional activation (64).  
 
DNA methylation is the transfer of a methyl group from a methyl donor (S-adenosyl 
methionine) to the cytosine in a CG pair by a DNA methyl transferase enzyme which results 
in gene silencing. In normal cells, most non-promoter CG sites are methylated and promoter 
CG sites are un-methylated. A hallmark of cancer progression is an initial wave of global 
hypomethylation whereby previously methylated CG sites in intergenic regions become 
unmethylated. This is followed by local hypermethylation of CG sites in gene promoter 
regions. Hypermethylation, and therefore silencing, of tumor suppressors is a well 
documented phenomenon in the etiology of various tumor types (64).  
 
The presence of a CpG island in the survivin promoter suggests that survivin gene 
expression may be regulated by DNA methylation. Since survivin is transcriptionally silent 
in most normal adult tissue, many groups speculated that the survivin promoter would 
normally be methylated. However, the methylation status of the survivin promoter has been 
analyzed in several tissue types an in most cases it has been reported that the survivin 
promoter is unmethylated in normal tissues (29, 44, 60, 74, 82, 111, 118, 119). One report 
showed that the survivin promoter was methylated in normal ovarian tissue but 
hypomethylated in ovarian tumors. Since the expression status of survivin is similar in the 
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endometrium as it is in the ovary, we speculated that DNA hypomethylation could explain 
survivin overexpression in endometrial cancer.    
 
Purpose of project and rationale: 
 
We observed that survivin was overexpressed in high grade endometrial tumors and 
hypothesized that DNA hypomethylation could be responsible for this overexpression. We 
conducted methylation analysis and determined that the survivin promoter was 
hypermethylated not hypomethylated in EC progression. To explain this seemingly 
paradoxical result, we speculated that DNA methylation could activate survivin expression 
in tumors by inhibiting the binding of a transcriptional repressor.  In the subsequent work, 
we will present data supporting our hypothesis that DNA methylation of the survivin 
promoter functions to de-repress survivin expression in cancer cells by inhibiting the 
binding and repressive function of the tumor suppressor protein p53. 
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CHAPTER 2: SURVIVIN IS OVEREXPRESSED AND HYPERMETHYLATED IN 
ENDOMETRIAL CANCER. 
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Introduction 
 
Molecular progression of endometrial cancer 
Endometrial tumors are classified into two categories, Type I or Type II. Type I 
tumors are the most common, accounting for 80% of endometrial cancer cases. 
Histologically, these tumors are well-differentiated and endometrioid (resembling 
endometrial glands). These tumors are graded from 1-4 based on the level of cellular 
differentiation such that the most well-differentiated tumors are low grade (EC1) and have 
the best prognosis whereas high grade (EC3-4) tumors are poorly differentiated and have the 
worst prognosis (27, 90). Type I tumors commonly occur in pre- or peri-menopausal women 
who have a heightened exposure to estrogen and are generally preceded by endometrial 
hyperplasia (51). Common genetic mutations is the Type I tumors include the DNA 
mismatch repair enzymes (MLH1, MSH2, MSH6) (11), KRAS (56) , PTEN (73), and 
CTNNB1 (β-Catenin) (65) whereas TP53 mutations are extremely rare (<1%) (81). By 
contrast, Type II tumors are less understood, they are poorly differentiated and tend to be of 
the papillary serous, or clear cell types. These tumors are highly invasive and carry a poor 
prognosis (10). They tend to occur in older post-menopausal women and are not linked to 
hyper-estrogenic signaling or endometrial hyperplasia (75, 105). Genetically, these tumors 
commonly have alterations in TP53 (86). We will focus our studies on the Type I, more 
common tumor type. 
 
Epigenetic control in Endometrial Cancer 
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In Type I tumors, epigenetic studies have linked hypermethylation to the loss of 
expression of DNA repair enzymes MLH1 and O6-methylaguanine DNA methyltransferase 
(MGMT), the tumor suppressors PTEN, p53 and TIG1, the progesterone receptor, the β-
catenin/Wnt signaling regulator APC, the transcription factor C/EBPα, and the 
differentiation gene HoxA10 (34, 90, 117, 120). Alternatively, hypomethylation has been 
described as a contributing factor for oncogene over-expression in EC. The oncogene PAX2 
(90, 113) and the metastasis promoting gene S100A4 (114) were shown to be overexpressed 
and hypomethylated in aggressive endometrial cancer. Based on these observations, we 
hypothesized that survivin would be similarly hypomethylated in endometrial cancer. In this 
chapter we will explore 2 questions: 1.) Is survivin overexpressed in Type I endometrial 
tumors? 2.) What is the methylation status of the survivin promoter in normal endometria 
and endometrial tumors?  
 
Materials and Methods 
 
Human Endometrial Tissue 
All human tissue samples were obtained from patients under protocols approved by 
Institutional Review Boards at the University of Texas Health Science Center and MD 
Anderson Cancer Center. 
Gene expression was analyzed in fresh frozen tissues from 71 endometrioid
 
adenocarcinoma samples obtained
 
at the time of hysterectomy and submitted to the 
Department of Pathology, MD Anderson Cancer Center. Diagnoses were confirmed 
following
 
light microscopic examination of H&E-stained slides by a
 
gynecologic pathologist 
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at MD Anderson Cancer Center (Houston, TX).
 
Tissues were frozen in liquid nitrogen and 
stored at -80 C.  
Gene expression was analyzed in postmenopausal endometrial tissues obtained from 
a selected
 
subset (n = 10) of a large group of healthy postmenopausal women
 
(n = 210) 
participating in a clinical trial of estrogen replacement
 
therapy (ERT). These 210 women 
were randomly divided into three
 
groups receiving one of the following three treatments: 1) 
placebo;
 
2) conjugated estrogens (2:1, wt/wt) of estrone sulfate and α-equilin
 
(EES; 0.625 
mg/d, Wyeth Research, Philadelphia, PA);
 
or 3) Premarin (0.625 mg/d; Wyeth Research) for 
6 months under
 
conditions approved by the Human Ethics Committee of Escola
 
Paulista de 
Medicina Universidade Federal de São Paulo,
 
Brazil. Tissues were frozen in liquid nitrogen 
and stored at -80 C.
 
 
DNA methylation analysis was conducted on normal tissues derived from baseline 
endometrial biopsies from women with HNPCC mutations who were enrolled in a 
chemoprevention trial of depot medroxyprogesterone acetate (DEPO, Pfizer, New York, 
NY) versus combination oral contraceptives (0.03mg ethinyl estradiol/ 0.3mg norgestrel, 
Wyeth-Ayerst) for prevention of endometrial cancer. These women have a 71% lifetime risk 
of developing endometrial cancer, compared to 3% for the general population and tend to 
develop cancer 15 years earlier than patients from the general population(1, 11, 22, 39, 48, 
63, 112). The women enrolled in the study (n=68) either have known HNPCC mutations or 
fulfill Amsterdam criteria for HNPCC but have a histologically confirmed “normal” 
endometrium such that there is no evidence of endometrial cancer or its precursor, 
endometrial hyperplasia. Endometrial pipelle biopsies (n=10) were obtained under 
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conditions approved by the institutional review board
 
at the University of Texas M.D. 
Anderson Cancer Center. Tissues were frozen in liquid nitrogen and stored at -80 C.  
DNA methylation status was also analyzed in human endometrial cancer cells which were 
manually dissected from adjacent stroma in paraffin-embedded tumor sections using a 2.0 
mm biopsy punch (Fray Products Corp.). 
 
RNA extraction 
Frozen tissues were homogenized in TriReagent® (Molecular Research Center) and 
RNA was precipitated with isopropanol,
 
applied to RNeasy spin columns (Qiagen), eluted,
 
and treated with RNase-free DNase for 30 min at 37 C, followed
 
by heat inactivation at 75 C 
and storage at -80ºC.  
 
Quantitative Real Time-RT PCR (QPCR) 
Taq-Man assays utilize the 5’ nuclease activity of Taq DNA polymerase and an 
assay specific fluorogenic probe as a means to quantify the abundance of a transcript. The 
probe is designed with a fluorescent reporter dye (FAM) on the 5’ end and a quencher dye 
(BHQ1) on the 3’ end.   During the extension cycle, the DNA polymerase cleaves the 
reporter dye thereby releasing it from the quencher and subsequently a fluorescent signal is 
emitted and detected.  The fluorescent signal from the unknown samples is compared to the 
signal measured from a standard curve of synthetic DNA (sDNA) oligos designed to 
represent the amplicon of each assay. The sDNA is serially diluted in 10-fold decrements to 
represent a 5-log scale of fluorescent signal plotted against a known sDNA quantity from 
which fluorescent signal from unknown samples (CT) is interpolated into transcript quantity. 
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Taqman real-time quantitative assays for survivin and 18S rRNA were developed using 
Primer Express software (Applied Biosystems) based on sequences from GenBank. The 
assays were developed and all QPCR reactions were completed at the Quantitative 
Genomics Core Laboratory (UT-Houston Medical School, Houston, TX, USA). The primer 
and probe sequences and accession numbers for all assays are listed in Table1.  
Forty nanograms of RNA (10ng/µL) from each sample were reverse transcribed in 
triplicate on a 7700 format 96-well plate (ISC Bioexpress, Kaysville, UT) in 6 µL of 
reaction master mix containing 400nM assay-specific reverse primer, 500 µM 
deoxynucleotides, Stratascript buffer, and 10U Stratascript reverse transcriptase (Stratagene, 
Cedar Creek, TX). The assay of each sample also included a nonamplification control well 
which contained all reagents and RNA but was lacking the reverse transcriptase enzyme. 
The plate was incubated for 30 minutes at 50º followed by 20 minutes at 72º in a 
thermocycler. Afterwards, 40µL of PCR master mix containing 400nM assay specific 
primers, 100nM assay specific probe with a 5' 6-FAM
 
(5-carboxyfluorescein) and a 3' Black 
Hole Quencher 1 (BHQ1), 5mM MgCl2, 200µM deoxynucleotides, PCR buffer and 1.25U 
Taq polymerase was added to each well and amplified in an ABI Prism 7700 sequence 
detection system (Applied Biosystems, Foster City, CA) under the following cycling 
conditions: 95°C for 1 min, 40 cycles of 95°C for 12sec, and 60°C for 30 sec. The results 
were analyzed using SDS 1.9.1 software (Applied Biosystems) with SuperROX (BioSearch, 
Novato, CA) as a reference dye. The mean transcript levels for all assays were normalized to 
the housekeeping gene 18s ribosomal RNA transcript levels. Data are presented as a median 
ratio of (transcript/18s). 
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Assay 
(Type) 
Primer & Probe 
Sequences 
Accession# 
Survivin 
(Taqman) 
181+CCACTGCCCCACTGAGAAC                     
 255-GGCTCCCAGCCTTCCAG 
204+FAM-CAGACTTGGCCCAGTGTTTCTTCTGCT-BHQ1 
NM_001168 
18s rRNA 
(Taqman) 
1335+CGGCTTAATTTGACTCAACAC               
1401-ATCAATCTGTCAATCCTGTCC 
1359+FAM-AAACCTCACCCGGCCCG-BHQ1 
M10098 
ApoB100 
(Taqman) 
13503+CCTTTGAGGTCTTATTCACGAAT         
13579-AATGCAAGAAGAAAACCTAGGG  
13554-FAM-ACTTCTCTGGACATTGGCCTAGACA-BHQ1 
NT_022184 
Survivin 
(MSP) 
(M)FWD+GGCGGGAGGATTATAATTTTCG, (M)REV-CCGCCACCTCTACCAACG 
(U)FWD+GGTGGGAGGATTATAATTTTTG, (U)REV-
CCACCACCACCACCTCTAC 
U75285 
Survivin 
(pyrosequenci
ng) 
FWD+GGYGGGAGGATTATAATTTT  
REV-biotin-AAAAAAAACTACCAAACAAAAAAC 
SEQ+GTTTTTATTTTTAGAAGGT 
U75285 
Ki67 
(Taqman) 
3323+AAGTTCACACGGACGTCAG                         
3391-GATGCTCTTGCCATCTCC 
3347+FAM-ACCACGCACACGCACAGAGAG-BHQ1 
NM_002417 
cMYC 
(Taqman) 
1479+ACACATCAGCACAACTACGC                 
1540-CTCTTGGCAGCAGGATAGTC 
1501+FAM-CGCCTCCCTCCACTCGGAA-BHQ1 
NM_002467 
Survivin 
(gel-shift) 
Sense-GCCTAAGAGGGCGTGCGCTCCCGACATGCCCCGCGGCGCG  
Anti-sense-TGGCGCGCCGCGGGGCATGTC GGGAGCGCACGCCCTCTTA 
U75285 
Survivin 
(ChIP) 
Fwd-ACTACAACTCCCGGCACA  
Rev-AGAGATGCGGTGGTCCTTGAGAAA 
U75285 
Nek2 
(UPL) 
1372+AGTGCAAGGACCTGAAGAAAAG 
1417-TCAATATCTGACAGGGCTTGAG 
UPL#44 (universal probe library, Roche applied sciences) 
NM_002497.2 
HMGB1 
(UPL) 
5+GAGTAATGTTACAGAGCGGAGAGA 
56-AATGTACTGCAATGGCTGTGAG 
UPL#75 
NM_002128.4 
CDC25C 
(Taqman) 
39+ CCGTAACTTTGGCCTTCTGC 
111- CAGCTCTGCCTTCCGACTG 
86-FAM-CCAACGTCGGACTCAGAGTCTTCCCT-BHQ1 
NM_001790 
 
Table 1:  QPCR Primer and Probe Sequences 
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DNA isolation 
DNA was isolated according to TriReagent® protocol by phenol and chloroform 
separation, ethanol precipitation, and solubilization in 8mM NaOH. HEPES was used to 
adjust the pH to 8.4 prior to bisulfite treatment.  
Copy Number Variation (CNV) Assay 
Forty nanograms of genomic DNA from normal endometrial samples and from 
endometrial tumors isolated as described above were amplified by QPCR in a 25µL reaction 
volume consisting of: 1X PCR buffer, 5mM MgCl2, 200µM dNTPs, 400nM assay specific 
primers, 100nM assay specific probe and 1.25U Taq polymerase, and detected in an ABI 
Prism 7700 as described above. Survivin levels were normalized to the levels of the 
housekeeping gene ApoB that is located on chromosome 1 and does not exhibit CNV in 
tumors. The ApoB assay was designed within intron 10. Relative gene copy number was 
determined using the using the comparative delta Ct method by the formula 2
−(∆∆Ct+/−SD) 
where one normal sample is designated as the calibrator to which all other samples are 
compared. ∆∆Ct = (Ct ApoB calibrator − Ct Survivin calibrator) − (Ct ApoBsample − Ct 
Survivinsample). The Ct (cycles to threshold) is defined as the point (cycle) at which the 
fluorescence level rises above baseline (threshold). The mean relative copy number for all 
the normal samples was then compared to the mean relative copy number for all the tumor 
samples.   
 
Bisulfite Treatment of DNA 
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Sodium bisulfite has been used extensively in studies of DNA methylation because 
of its ability to preferentially deaminate unmethylated cytosines and convert them to uracils. 
The uracil is then read as an adenine during polymerase based amplification methods and 
the final result is a sequence with a C to T mutation. Methylated cytosines are protected 
from the deamination reaction and therefore no conversion occurs. This allows for 
discrimination between methylated and unmethylated cytosines. Bisulfite modification of 
2µg of DNA was performed by using the EZ DNA Methylation-Gold Kit™ (Zymo Research 
Corp., Orange, CA) according to manufacturer protocol.  DNA was heat denatured for 10 
minutes at 98ºC and treated with a sodium bisulfite conversion reagent for 2.5 hours at 64ºC 
in a thermocycler.  This step serves to hydrolytically deaminate all unmethylated cytosines 
into uracils whereas methylated cytosines remain as cytosines. The resultant uracil from the 
deamination reaction is concomitantly sulphonated by the sodium bisulfite and must 
therefore be desulphonated. This is achieved by addition of the sample to a provided spin 
column and treatment with an alkali desulphonation buffer. The DNA is then washed and 
eluted through a series of spins and stored at -20ºC until subsequent analysis.   
 
To determine if bisulfite conversion was successful, two sets of primer pairs were 
designed downstream of the Survivin promoter in Exon 4 where none of the cytosines are 
subject to methylation and should therefore all convert to thymidine. One primer pair was 
designed to reflect the bisulfite converted condition where all cytosines are converted to 
thymidines and the second primer pair was designed to reflect the untreated condition for 
which all cytosines maintain identity. Each bisulfite treated DNA sample was PCR 
amplified in parallel with each set of primers and the PCR product was subject to gel 
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electrophoresis and visualized by ethidium bromide staining. Only, samples for which there 
was a bright “converted” band were included for further analysis.  Primer sequences are: 
Converted                                                 Unconverted  
F: 5’-GTGTTGTTGGTAATAGTGGTT        F: 5’-GTGCTGCTGGTAACAGTGG 
R: 5’-CATAAAATCCAAACACATTCA        R: 5’-CATGAGGTCCAGACACATTCA  
 
Metylation specific PCR (MSP)  
Bisulfite treated DNA from 5 normal endometrial tissue and 15 endometrioid 
adenocarcinomas was PCR amplified in parallel in a 10µL reaction volume under the 
following conditions: 1X PCR buffer (16.6 mM ammonium sulfate, 67 mM Tris-HCL pH 
8.8, 6.7 mM MgCl2, 10 mM -mercaptoethanol), 0.5mM dNTPs, 200nM  specific 
methylated or unmethylated PCR primer pairs and 0.5U HotStart Taq DNA polymerase 
(Qiagen). Thermocycler condition were: 15min. at 95ºC, 35 cycles of 30sec. at 95ºC, 30sec. 
at 55ºC and 30sec. at 72ºC followed by a final extension step of 10min. at 72ºC.  PCR 
product was subject to gel electrophoresis on a 6% 0.5X TAE polyacrylamide gel and 
visualized by ethidium bromide staining.  
 
Bisulfite Pyrosequencing™ Analysis 
PCR reactions were carried in 50 µl reaction volume including 2 µl bisulfite treated 
DNA, 16 mM (NH4)2SO4,67 mM Tris-HCl (pH 8.8), 1 mM 2-mercaptoethanol 2 mM 
MgCl2, 0.125 mM dNTP, 1 unit Taq polymerase, and 200 nM primers. Results were 
quantitated using the PSQ HS 96Pyrosequencing System (Pyrosequencing Inc) at the UCLA 
Sequencing Core in the Department of Human Genetics. Three of the samples were spiked 
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with 100%, 25% and 10% in vitro methylated DNA to monitor the efficiency of the 
pyrosequencing reaction. The assay is biased against methylation such that the measured 
percentages for the 100%, 25% and 10% methylated samples were 32%, 6% and 3% 
respectively. We conducted linear regression analysis and generated a standard curve with a 
99% correlation coefficient to correct for this assay bias.  
 
Sss1 in vitro Methylation 
To validate the ability of the MSP and Pyrosequencing assay to detect methylation, 
DNA samples were methylated in vitro using the CpG Methylase M.SssI (New England 
Biolabs, Ipswich, MA) which is isolated from a strain of E. coli. containing the methylase 
gene from Spiroplasma sp. strain MQ1.  DNA was methylated according to manufacturer 
protocol. The DNA sample is incubated for 2 hours at 37ºC with Sss1 methylase, the 
supplied buffer, and the methyl donor S-adenosyl-methionine (SAM). Sss1 non-specifically 
transfers a methyl group from SAM to any CpG quartet. The reaction is stopped by heating 
at 65ºC for 20 minutes and the DNA is purified by phenol extraction followed by ethanol 
precipitation and then subject to bisulfite treatment and PCR amplification.  
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Results 
Survivin is overexpressed in endometrial cancer 
Using quantitative RT-PCR (QPCR) we quantified survivin transcript levels from 10 
normal post menopausal endometrial samples and 71 endometrioid adenocarcinoma 
samples. Survivin mRNA levels progressively increased from normal to grade 3 tumors 
(median: normal= 0.06, EC1= 0.42, EC2= 0.89, EC3= 1.32) and were significantly 
increased 14.9 fold in grade 2 and 22.7 fold in grade 3 endometrial tumors compared to 
normal samples (Figure 4). This suggests that survivin overexpression is selective towards 
high grade, poorly differentiated tumors. This finding is consistent with RT-PCR and 
immunohistochemistry data from other laboratories (26, 27, 57, 99). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4:  Survivin is overexpressed in endometrial cancer 
QPCR analysis of survivin expression in normal endometria and grade1 to grade 
3 endometrial tumors (EC1-EC3). Data is presented as a median ratio of 
survivin/18s rRNA*(10
5
) ± interquartile range. *p<0.001 by Kruskal-Wallis 
non-parametric two-way ANOVA and Dunn’s post test 
 Nabilsi et al, Oncogene 2009 
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Survivin overexpression in endometrial cancer is not due to gene amplification 
Two common causes of oncogene overexpression in cancer are activating SNPs (single 
nucleotide polymorphisms) and gene amplification. To date there are no known activating 
SNPs reported for survivin in any pathology (3), however survivin gene amplification has 
been reported in neuroblastoma (98). To determine if survivin overexpression in endometrial 
cancer is due to amplification of the survivin gene, we conducted a copy number variation 
(CNV) assay. Survivin gene copy number was quantified by QPCR in 5 normal and 14 
tumor samples and normalized to the copy number of the gene apolipoprotein B100 (ApoB). 
ApoB is a known single copy gene (per haploid genome) located on chromosome 2 (42). A 
requisite for normalizing survivin levels to ApoB levels is that the efficiency of the two 
assays must be similar. We generated a standard curve for each assay by quantifying gene 
copy levels in 5 serial half dilutions of DNA quantity (50ng, 25ng, 12.5ng, 6.25ng, and 
3.125ng), plotting the detected CT values as a function of the DNA quantity, and conducting 
linear regression analysis (Figure 5a and 5b). The efficiency of each assay is reflected by 
the slope of the line generated by the standard curve such that 100% efficiency= -3.33. The 
slopes of the survivin assay  and ApoB assay were both -3.43 thus we were confident in the 
utility of ApoB to normalize for survivin. We observed no difference between the survivin 
copy number detected in normal tissue (mean= 1.32) compared to endometrial tumors 
(mean= 1.33); p=0.83 (Figure 6). We concluded that the overexpression of survivin 
observed in endometrial tumors is not due to gene amplification. 
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Figure 5: Comparison of efficiency for survivin and ApoB CNV QPCR assays  
Regression analysis was used to determine the QPCR assay efficiency for (a.) survivin 
and (b.) ApoB to detect gene copy number as a function of a known DNA quantity. 
The efficiency is determined by the slope of the line such that 100%= -3.33. Both 
assays had a slope= -3.43. 
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Figure 6: Survivin overexpression in endometrial cancer is not due to gene 
amplification 
CNV analysis of 5 normal endometria and 14 high grade endometrial tumors. Data are 
presented as the relative ratio of survivin gene copy number normalized to ApoB gene 
copy number. Details for the relative quantification equation are given in the materials 
& methods. An unpaired Student’s t test was used for statistical analysis. 
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Examination of the survivin promoter indicated the presence of a canonical CpG 
island which suggests that survivin may be regulated by DNA methylation. Given the 
expression status of survivin, we hypothesized that the survivin promoter was methylated in 
the normal endometrium then becomes hypomethylated throughout EC progression.    
  
The survivin promoter is hypermethylated in endometrial cancer 
Surprisingly, analysis of the survivin promoter with methylation specific PCR (MSP) 
showed that normal endometrial samples were completely unmethylated whereas 
methylation progressively increased from low grade to high grade endometrial tumors 
correlating with increased survivin expression (Figure 7a). In an independent set of normal 
and endometrial tumor samples, we used bisulfite pyrosequencing to analyze the 
methylation status of 12 CpG sites within the 5’ untranslated region of Exon 1. We observed 
that only 11% of the CpGs have at least 10% methylation in normal samples compared to 
33% of the CpGs being methylated in tumors, p=0.012 (Figure 7b). Our MSP and 
pyrosequencing data both showed increased methylation that correlated with survivin over-
expression; this suggested that DNA methylation of the survivin promoter may inhibit the 
binding of a transcriptional repressor. The tumor suppressor protein p53 is a well 
documented repressor of survivin (28, 43, 69) and the p53 binding site in the survivin 
promoter contains three internal CpG sites. Pyrosequencing data showed that none of the 
normal samples are methylated at the p53 binding site whereas 64% of the tumors are 
methylated at this site (Figure 7c). Furthermore, expression analysis of these tumors 
indicated that survivin expression increased with increasing methylation at the p53 binding 
27 
site. We hypothesized that DNA methylation could inhibit p53 binding thereby relieving 
survivin of p53 mediated transcriptional repression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Methyl-
CpGs in bs
Survivin 
expression
o
o
1
2
3.39e-5
4.37e-5
8.24e-5
21.2e-5
p53 binding site
p=0.02
 
a. 
b. c. 
28 
 
 
 
 
 
 
 
 
 
 
Discussion 
We have explored the expression and methylation status of survivin in the human 
endometrium. We observed by QPCR that survivin is overexpressed in endometrial tumors 
compared to normal endometria and that this overexpression is not caused by survivin gene 
amplification. Another potential cause of survivin overexpression in EC could be mediated 
by RNAi (RNA interference). RNAi occurs when complementary RNA strands bind and 
form a double stranded RNA which will results in either (1.) a secondary structure that 
inhibits the translational  machinery from translating the transcript or (2.) activation of the 
endoribonuclease Dicer to bind and degrade the RNA duplex. Since the survivin transcript 
lies antisense to the EPR-1 transcript, there could be an RNAi mediated interaction between 
them which would alter gene expression. It was reported that both transcripts are expressed 
in various hematological cell types but EPR-1 expression was dominant in normal cells 
Figure 7: Methylation analysis of the survivin promoter 
(a) MSP analysis of 5 normals and 15 EC tumors. Each number represents 1 DNA sample 
amplified with primers which detect methylated (M) or un-methylated (U) survivin 
sequences. (b.) Pyrosequencing analysis of DNA from normals (n=5) and EC tumors (n=11). 
Mean % of CpG sites methylated in normal vs. tumor samples depicted graphically; p=0.02 
determined by Mann-Whitney unpaired t-test. (c.) Each circle represents a CpG site, unfilled 
circles represent unmethylated sites and filled circles indicate methylation. Increased darkness 
corresponds to increasing % methylation.  Tumors are stratified according to the number of 
CpG sites methylated in the p53 binding site (bs) and the corresponding mean survivin levels 
are indicated. Data are presented as a mean ratio of survivin/18srRNA.   
 
 Modified from Nabilsi et al Oncogene 2009 
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while survivin expression was low and survivin expression was dominant in several cancer 
cell lines and leukemias while EPR-1 expression was low (79, 115). Furthermore, 
transfection of EPR-1 into colon cancer cells drastically reduced survivin expression through 
an RNAi mediated mechanism (115). To determine if a similar mechanism exists in 
endometrial cells, we designed a Taqman QPCR assay with an EPR-1 strand specific probe 
and measured EPR-1 transcript levels in normal endometria and in endometrial tumors. If 
survivin expression is modulated by EPR-1 levels then we expected to find high levels of 
EPR-1 in normal tissue and progressive loss of EPR-1 throughout EC progression. We 
found that EPR-1 transcript was not detectable in any normal tissue or tumor samples, nor in 
any endometrial cancer cell lines (data not shown). We concluded that aberrant EPR-1 
expression does not contribute to survivin overexpression in EC.   
 
Epigenetic studies utilizing two different bisulfite methodologies, MSP and 
pyrosequencing in two independent sets of normal endometria and endometrial tumors 
indicated that the survivin promoter is unmethylated in normal endometrial tissue and is 
hypermethylated in EC. While this pattern follows the hallmark pattern of DNA methylation 
whereby most gene promoters are unmethylated in normal tissue then become methylated in 
tumors, this was an incredibly surprising result since hypermethylation is generally 
associated with gene silencing, not gene activation. Mechanistically, one potential 
explanation for increased methylation correlating to increased expression is that the presence 
of methylation at this promoter could inhibit the binding of a transcriptional repressor. The 
most well-documented repressor of survivin expression is the tumor suppressor protein p53 
30 
and the p53 binding site in the survivin promoter lies within the hypermethylated CpG 
island.  
 
Our working model is that in the normal endometrium, where the p53 binding site is 
unmethylated, p53 is able to bind and repress survivin expression (Figure 8a.). In contrast, in 
endometrial tumors, where the p53 binding site is methylated, p53 binding is inhibited thus 
relieving survivin of p53 mediated repression (Figure 8b). The inhibition of p53 binding can 
be achieved either directly by the presence of the methyl groups themselves or through the 
recruitment of methyl binding proteins to the methylated DNA. Furthermore, the p53 
binding site in the survivin promoter overlaps an E2F binding site which has been shown to 
bind the transcription factor E2F1 and activate survivin expression. The E2F binding site has 
only 1 CpG site and is therefore less likely to be inhibited by DNA methylation as p53 
which contains 3 CpG sites. Thus, a third scenario is that DNA methylation at the p53/E2F 
binding site results in inhibition of p53 binding and preferentiates E2F1 binding which 
further increases survivin expression (Figure 8c). In the next chapter, we will validate that 
p53 represses survivin in our model system. 
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Figure 8: Model for activation of survivin by DNA methylation 
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Introduction 
 
“If genius is the ability to reduce the complicated to the simple, then the study of p53 
makes fools of us all” (109)  
 
The tumor suppressor protein p53 is a transcription factor that is activated following 
a variety of cellular stress signals. This signal can include several types of DNA damage, 
telomere shortening, hypoxia, mitotic spindle dysfunction, and temperature shock (108). 
These stress signals are detected by various proteins that modify the p53 protein or its 
negative regulator, MDM2. MDM2 is a ubiquitin ligase that blocks p53 transcriptional 
activity and mediates its degradation. After a stress signal, MDM2 polyubiquitylates itself 
thus targeting its own destruction, and subsequently increases the half-life of p53 from 
minutes to hours allowing for its accumulation, modification and action (110). The 
stabilized p53 protein (phosphorylated, methylated and/or acetylated at specific serine or 
lysine residues) binds as a tetramer to its targets’ p53 binding sites and activates or represses 
transcription in order to arrest a cell for repair of DNA damage or, if the damage or insult is 
beyond repair, signal for apoptosis (58, 59). The result of p53 signaling is to maintain the 
genomic integrity of the cell and thereby prevents cancer. Perturbations of proper p53 
function increases a cell’s tumorigenic potential. This is evident by the fact that nearly 50% 
of all tumors contain p53 mutations (85).      
 
p53 is a well documented survivin repressor and examination of the survivin 
promoter indicates that the p53 binding site contains 3 internal CpG sites which gain 
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methylation in endometrial tumors (Figure 4c). We suspect that methylation at the p53 
binding site will inhibit p53 from binding to and repressing survivin. Several approaches 
have been used to demonstrate survivin repression by p53 including UV irradiation (43), 
doxorubicin treatment (28, 43) and p53 over-expression (69) in a variety of cell types but 
this regulation has not been examined in endometrial cells. In this chapter we will validate 
that p53 represses survivin in endometrial cancer cells.  
   
Materials and Methods 
 
Cell culture 
Ishikawa endometrial cancer cells (ATCC) were maintained in RPMI1640 medium 
(Gibco) supplemented with 10% FBS, 1U/mL penicillin/ 1ug/mL streptomycin, and 10mM 
Hepes. HCT116wt and HCT116 p53
-/-
 colon cancer cells (a generous gift from Dr. Bert 
Vogelstein) were maintained in McCoy’s 5a growth medium (Gibco) supplemented with 
10% FBS and 1U/mL penicillin/ 1µG/mL streptomycin. All cells were maintained in a 
humidified 37ºC incubator with 5% CO2. 
 
Drug treatment 
Cells were grown to 60% confluency then treated with 0.5µM, 1µM or 2µM 
doxorubicin (Sigma) or vehicle (sterile water) as indicated for 48hrs. 
 
Western Blot 
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Whole cell lysate 
Cells were lysed by incubation for
 
1 hour at 4°C in 100 µL Triton lysis buffer [1% 
Triton
 
X-100, 150 mmol/L NaCl, 25 mmol/L Tris (pH 7.5), 1 mmol/L glycerol
 
phosphate, 1 
mmol/L sodium fluoride, and 1X Complete Mini Protease Inhibitor Cocktail  (Roche
 
Applied Science, Indianapolis, IN)]. Lysates were centrifuged
 
for 10 minutes at 14,000 x g 
at 4°C. Supernatants were saved
 
and boiled for 5 minutes with SDS-PAGE sample
 
buffer (50 
mmol/L Tris-HCL, 2% SDS, 0.1% bromophenol blue, 10%
 
glycerol, and 5% ß-
mercaptoethanol). Samples then resolved by SDS-PAGE, and electrophoretically transferred 
to nitrocellulose membranes. Membranes were incubated overnight
 
at 4°C with primary 
antibodies specific for survivin (Cell Signaling Technology), p53 (Calbiochem) and β-actin 
(Millipore). Membranes were incubated with species-specific secondary antibodies then 
visualized
 
by chemiluminescence. 
 
Nuclear protein isolation 
Cells were scraped into 1X PBS on ice then resuspended in a 0.5% Triton lysis 
buffer (10mM HEPES-KOH, 1.5mM MgCl2, 10mM KCl, 0.5mM DTT, and 1X Complete 
Mini Protease inhibitor cocktail (PIC)). Following centrifugation the supernatant was 
removed and the remaining nuclear pellet was resuspended in a 25% glycerol buffer (20mM 
HEPES-KOH, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 0.5mM DTT and 1X PIC) and 
kept on ice for 30 minutes with agitation. Following centrifugation the nuclear protein was 
collected and the western blot conducted as described above.  
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Plasmids 
We obtained a GFP-tagged p53 overexpression construct (Clontech, pp53-EGFP) 
from Dr. Donehower’s laboratory at Baylor University. We mutagenized nucleotide 580 in 
the p53 coding sequence from C to T so that the mutant protein will have a phenylalanine 
instead of leucine at amino acid 194. This residue is in the DNA binding domain of p53 so 
the L194Fmutant is incapable of binding to DNA (69). Mutagenesis was conducted 
according to the Statagene quick-change mutagenesis kit with the primers:  
L194F+: CCCCTCCTCAGCATTTTATCCGAGTGGAAG 
L194F-: CTTCCACTCGGATAAAATGCTGAGGAGGGG 
Successful mutagenesis was confirmed by DNA sequencing. 
 
We obtained a survivin-luciferase construct from Dr. Mien Chi Hung at M.D. 
Anderson Cancer Center and subcloned 980bp of the survivin promoter into a CpG-free-
luciferase vector (a kind gift from Dr. Michael Rehli at the University of Regensburg in 
Germany). This vector has been modified such that all of the CG dinucleotides in the vector 
backbone have been removed (52).  We also obtained a p53-luciferase reporter (luciferase 
driven by several repeats of p53 binding sites) from Dr. Russell Broaddus at M.D. Anderson 
Cancer Center to confirm that our GFP-tagged p53 protein but not our L194F mutant can 
sufficiently activate transcription of p53 target genes. We co-transfected each reporter with 
an internal control vector of Renilla luciferase driven by the thymidine kinase promoter 
(TK-Renilla).  
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Luciferase Assay 
 Cells were trypsinized and seeded to 60% confluency in a 60mm plate then co-
transfected with either the p53-luciferase or the survivin-luciferase constructs and TK-
Renilla as an internal control for transfection efficiency. The next day, transfected cells were 
trypsinized and re-seeded into 24-well plates, allowed to recover for four hours then either 
treated with drug or transfected with the wt-p53-GFP or L194F-GFP vectors. Forty-eight 
hours after treatment, cells media was replaced with 1X PBS and cells were harvested in 
Promega passive lysis buffer. Lysates were then incubated with Promega Dual-Glo 
luciferase substrate for 10 minutes according to manufacturer protocol and transferred to 
polystyrene tubes for photon emission measurement. Each sample is measured in duplicate 
for 10 seconds with a Monolight 2010 luminometer. Following firefly luciferase activity 
measurement, a second reagent was added to each sample to quench the firefly-luciferase 
signal and to allow for measurement of Renilla luciferase activity following the same 
detection parameters. Data are presented as a mean ratio of firefly/Renilla luciferase in 
relative units (RU).         
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Results 
 
Survivin is repressed by endogenous p53 
To validate that p53 represses survivin expression in endometrial cells, we treated 
Ishikawa endometrial cancer cells with the drug doxorubicin (adriamycin). Doxorubicin is a 
chemotherapeutic agent that acts as a topoisomerase II (topoII) poison. TopoII binds to and 
unwinds DNA during transcription. Doxorubicin intercalates into DNA and stalls TopoII 
thereby activating a DNA damage response which marks the cell for apoptosis. p53 is one of 
the proteins activated by doxorubicin and treatment of cells with doxorubicin to induce the 
nuclear accumulation of p53 is a common technique used to study endogenous p53 function 
and gene regulation (38, 76, 80, 93, 100). Ishikawa cells are a well-differentiated 
endometrioid adenocarcinoma cell line that harbor a silent mutation in p53 that function as 
wild-type (103). 
 
 Immunoblot analysis showed a dose dependent increase in the nuclear accumulation 
of p53 following 1uM and 2uM doxorubicin (doxo) treatment that correlated with decreased 
survivin levels in Ishikawa cells (Figure 9a). Similarly, Ishikawa cells transfected with a 
survivin-luciferase reporter showed a significant dose dependent decrease in survivin 
promoter activation following doxorubicin treatment (0.5uM doxo= 37% repression, 1uM 
doxo= 69% repression, p<0.05, and p<0.005 respectively) (Figure 9b).  
 
To confirm that the observed repression of survivin following doxorubicin treatment 
is dependent on p53, we treated wild-type and p53-null HCT116 colon cancer cells with 
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doxorubicin and conducted immunoblot analysis. We observed that survivin was repressed 
in the wild-type cells, but not in the p53-null cells following doxorubicin treatment (Figure 
10a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This finding is consistent with previous reports that repression of survivin by doxorubicin is 
mediated through p53 (28). E2F1 has been reported to be induced by doxorubicin (68) and 
serves as a control for drug induction in both wild-type and p53-null cells. Furthermore, 
transfection of the HCT116 cells with the survivin-luciferase reporter followed by 
doxorubicin treatment also showed decreased survivin promoter activation in response to 
 
Figure 9: endogenous p53 represses survivin in endometrial cancer cells 
Ishikawa cells were treated with doxorubicin (doxo) for 48 hrs. then harvested for (a.) 
immunoblot analysis or (b.) luminescence measurement. Control cells were treated with 
vehicle. B-actin serves as a loading control. *p<0.05, **p<0.005 by ANOVA followed by 
Bonferroni ad hoc post test.  
 Modified from Nabilsi et al Oncogene 2009 
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doxorubicin in the wild-type cells but not in the p53-null cells (Figure 10b) indicating that 
the repressive effect of doxorubicin on the survivin promoter is dependent on p53.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Survivin repression by exogenously expressed p53 is dependent on DNA binding 
 We have shown that activation of endogenous p53 represses survivin protein 
expression and promoter activity. Next we wanted to determine if expressing exogenous p53 
would repress survivin and if this repression was dependent on DNA binding. We obtained a 
 
Figure 10: Doxorubicin mediated repression of survivin is dependent on p53 
Wild-type and p53-null HCT116 colon cancer cells were treated with 1µM doxorubicin 
for 48 hrs. then harvested for (a.) immunoblot analysis or (b.) luminescence measurement. 
Control cells were treated with vehicle. B-actin serves as a loading control and E2F1 
serves as a control for drug induction. 
   Modified from Nabilsi et al Oncogene 2009 
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p53-GFP expression construct (a kind gift from Dr. Donehower) and mutagenized it to 
generate an L194F mutant that does not bind to DNA (69). This is one of the common “hot 
spot” mutations of p53 in human tumors and is the endogenous p53 mutation in T47D breast 
cancer cells (103). To confirm that wt-p53-GFP but not L194F-GFP can bind to and activate 
p53 target genes, we transfected a p53-luciferase reporter (luciferase driven by several 
repeats of p53 binding sites) with either wt-p53-GFP or L194F-GFP into p53-null HCT116 
cells. We observed a 16-fold increase in p53 activity in response to wt-p53 expression but 
no change in response to the L194F DNA binding mutant indicating that wt-p53-GFP but 
not L194F-GFP can activate p53 target genes (Figure 11a).  
  
To determine the effect of exogenously expressed p53 on survivin protein, we 
transfected wt-p53-GFP and L194F-GFP into Ishikawa cells and conducted immunoblot 
analysis. We observed that transfection of 2ug of the wt and mutant vectors resulted in 
equivalent expression of p53 but only the wt-p53 protein caused repression of survivin, not 
the DNA binding mutant (Figure 11b). Taken together, these data confirm that p53 represses 
survivin in endometrial cancer cells and that this repression is dependent on DNA binding.     
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Discussion   
 We have confirmed that survivin is repressed by p53 in endometrial cancer cells 
through induction of endogenous p53 protein by doxorubicin treatment and by expression of 
exogenous p53 protein. This finding is consistent with data reported by several groups in 
various model systems. It is interesting that p53 seems to exert a “basal” regulation of 
survivin expression. Most p53 target genes require not only the presence of p53 but also 
some form of activation of p53 to cause any changes in gene expression. For example, 
conditional “knock-in” of p53 into transgenic p53 knockout mice requires further activation 
of p53 by UV treatment in order to observe changes in c-Myc expression (67). However in 
Ishikawa cells, expression of wt-p53 through transient transfection was sufficient to cause 
survivin repression without any further p53 activation (Figure 11). This is also evident by 
the higher baseline survivin expression and promoter activity in the wild-type HCT116 cells 
compared to the p53-null cells (Figure 10). It is tempting to speculate that the increased 
presence of survivin in cells is so threatening to genomic stability that p53 is primed to 
repress this protein.  
Figure 11: exogenous wt-p53 represses survivin in endometrial cancer cells 
(a.) HCT116 p53-null cells were co-transfected with a p53-luciferase reporter and wt-p53-
GFP or L194F-GFP then harvested for measurement of luminescence. n=3, **p<0.005 by 
ANOVA followed by Bonferroni ad hoc post test. (b.) Ishikawa cells were transfected with 
wt-p53-GFP or L194F-GFP and harvested for Immunoblot analysis. B-actin serves as a 
loading control.  
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One of the oncogenic stimuli for p53 activation is c-Myc overexpression signaling 
through p19/ARF. Perhaps survivin is similarly not only regulated by p53 but is also capable 
of activating p53 in an auto-inhibitory fashion? I am not aware of any reports indicating that 
survivin can elicit a post-translational modification of p53 (i.e. phosphorylation, 
methylation, acetylation) but this may explain this unique activation-independent 
phenomenon. It would be interesting to transfect survivin cDNA into cells and to see if there 
is any effect on p53 stabilization. 
 
 Another interesting observation is that the basal activity of the survivin promoter in 
the luciferase experiments is quite high. Although this is consistent with previous reports, it 
is curious that survivin promoter activity is so robust in cancer cells without any external 
stimulus. It would be interesting to see if altering the amount of serum in the cell culture 
media has any effect on the baseline activity levels or if it is independent of growth stimuli. 
We have shown that treating Ishikawa cells with 1uM doxorubicin causes a 69% repression 
of survivin-luciferase activity however the equivalent treatment in HCT116 wild-type cells 
only caused a 30% repression. We believe this is because the baseline expression of 
survivin-luciferase in the HCT116 cells is much higher than in the Ishikawa cells and 
therefore dampened the effect. Without normalizing to TK-Renilla, the baseline activity of 
survivin-luciferase in Ishikawa cells is approximately 100,000 units whereas in HCT116 
cells it is 600,000 units. Normalizing these data brings both figures down to the 100-200 
R.U. range indicating that TK-Renilla is also highly expressed in the HCT116 cells 
compared to the Ishikawa cells. This suggests that the overall transfection efficiency is much 
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higher in the HCT116 cells than in the Ishikawa cells which may explain the differences in 
basal activity between the two cell types. 
 
 We have confirmed that survivin is repressed by p53 in our model system. In the 
next chapter we will explore the effect of DNA methylation on the ability of p53 to regulate 
survivin expression.          
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CHAPTER 4: DNA METHYLATION INHIBITS P53 MEDIATED SURVIVIN 
REPRESSION 
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Introduction 
The current understanding of gene regulation by DNA methylation in cancer 
progression is that once a tumor suppressor gene’s promoter gets methylated, DNA methyl 
binding proteins get recruited to the site of methylated DNA and inhibit the binding of the 
transcriptional machinery to that gene’s promoter. In many cases, the methyl binding 
proteins recruit histone modifiers (ie histone deacetylases) which modify the chromatin to be 
repressive to transcription (64). Evidence for DNA methylation inhibiting the binding of 
specific transcription factors to DNA is scarce. This is surprising since methylation 
interference (and protection) assays have been widely used in the past to determine the DNA 
binding regions of various proteins.  
 
The methylation interference assay was developed by the Walter Gilbert laboratory 
to study the specific interacting regions
 
of E. coli RNA polymerase with DNA (92).  In most 
cases this involved methylating guanine and adenine residues in the major groove of the 
DNA helix and looking for interference with DNA-protein binding however, the protocol 
was expanded to include cytosine methylation interference and many publications cite 
cytosine methylation interference of DNA-protein interactions (17, 45, 91). This cytosine 
methylation interference has been largely overlooked in the field of cancer epigenetics. 
More recently however, it has been published that DNA methylation of the hTERT (human 
telomerase) promoter activates its transcription by inhibiting the binding of CTCF (CCCTC 
binding factor), an hTert repressor (37, 83, 84). Similarly, gel shift studies indicate that 
DNA methylation can inhibit the binding of various E2F family members in a promoter 
specific context (14).  
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We have observed a correlation between increased survivin expression and increased 
survivin promoter methylation. We have also validated that p53 represses survivin 
expression in HCT116 colon cancer cells. In this chapter we will explore 3 questions: 1.) 
Does DNA methylation regulate survivin gene expression (or do they just correlate)? 2.) Is 
regulation of survivin by DNA methylation dependent on p53? 3.) Does DNA methylation 
of the survivin promoter inhibit p53 binding? 
  
Materials and methods 
 
Cell culture 
HCT116wt and HCT116 p53
-/-
 colon cancer cells (a generous gift from Dr. Bert 
Vogelstein) were maintained in McCoy’s 5a growth medium (Gibco) supplemented with 
10% FBS and 1U/mL penicillin/ 1µG/mL streptomycin. All cells were maintained in a 
humidified 37ºC incubator with 5% CO2. 
 
Drug treatment 
HCT116 cells were seeded to 20% confluency overnight then maintained in 2µM or 
200nM decitabine (5-Aza-2-deoxycytidine) (Sigma) as indicated or vehicle for 4 days. Due 
to the instability of the drug, media was changed daily with fresh drug application. 
 
Methylation Specific PCR (MSP), QPCR and Western Blot 
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 Following the drug treatment described above: genomic DNA, RNA and protein 
were isolated and analyzed by MSP, QPCR and western blot respectively, as described in 
Chapter 2.    
 
Cell cycle assay 
A commonly used dye for cell cycle analysis is propidium iodide. The dye 
intercalates into the major groove of double-stranded DNA and produces a fluorescent 
adduct that can be excited at 488 nm with an emission around 600 nm. The amount of signal 
reflects the DNA content of a cell and the stage of the cell cycle can then be inferred. Cells 
with 2N (diploid) DNA content are likely in G1, cells with 4N DNA content are in G2/M 
and cells with DNA content in between 2N and 4N are at some point of replication in S-
phase. HCT116 cells were treated with decitabine or vehicle as indicated for 4 days then 
harvested for cell cycle analysis. Cells were trypsinized and washed in 1XPBS then 
resuspended in propidium iodide buffer containing 50 µg/mL propidium iodide, 0.1% 
Triton-X 100, and 0.1% sodium citrate in 1X PBS. Samples were stored at 4°C for 2hrs. 
then vortexed and analyzed for DNA content by flow cytometry in a Guava® Personal Cell 
Analysis (PCA)-96 Flow Cytometer. Results were exported into excel for data analysis. 
 
Gel-shift assay 
Single stranded oligonucleotide probes representing the combined p53/E2F binding 
site in the survivin promoter were duplexed by heating to 95ºC then slowly cooling to 4ºC 
over 2 hrs. The probe is designed such that duplex will contain 3nt overhangs on the 3’ ends 
to aid in increased labeling efficiency. Duplexed probe was column purified then methylated 
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according to SssI protocol described in Chapter 1. Methylation efficiency was monitored by 
digestion with the CpG methylation sensitive enzyme HinPI and polyacrylamide gel 
electrophoresis followed by ethidium bromide staining and visualization. We observed that 
1hr. of incubation with the SssI methylase and S-adenosyl methionine (methyl donor) was 
sufficient to protect the probe from HinPI digestion (Figure 12a).  
 
Methylated and unmethylated probe were then labeled with the Biotin 3' End
 
DNA 
Labeling kit (Pierce Biotechnology) according to manufacturer’s protocol.
 
Biotinylation 
efficiency was estimated by dot blot analyses
 
against control oligonucleotides. We observed 
an equivalent 25-30% labeling efficiency for both probes (Figure 12b). Binding
 
reactions 
(RT, 20 min) contained 20ng purified p53 protein (Active Motif), buffer (10 mM Tris pH 
7.5, 50 mM KCl, 5 mM MgCl2, 1
 
mM dithiothreitol, 0.05% TX-100, 2.5% glycerol), 1 µg
 
poly(dI-dC), and 2 nM of methylated or unmethylated biotinylated survivin probe. Protein-
DNA complexes were resolved
 
on 5% Tris borate-EDTA gels, transferred to nylon
 
membranes, and visualized utilizing the Chemiluminescent Nucleic Acid Detection Module 
(Pierce Biotechnology) according to manufacturer’s protocol. Some reactions
 
were 
preincubated for 10 min with 200-fold excess of unlabeled
 
probe and/or an anti-p53 
antibody (Active Motif) before adding biotinylated probe.  
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For the E2F1 gel shift, HCT116 p53-/- cells were transfected with a CMV-E2F1 
overexpression vector (Addgene plasmid 10736- 408 pSG5L HA E2F1), and synchronized 
into S-phase by overnight serum withdrawal followed by 12hr. serum rescue to promote 
E2F1 accumulation in the nucleus. E2F1 enriched nuclear lysates were then prepared with 
NE-PER nuclear and cytoplasmic extraction kit (Pierce). Probes were incubated with 5µg 
nuclear lystae and analyzed as described above. Some reactions
 
were preincubated for 10 
min with 200-fold excess of unlabeled
 
survivin probe or anti-E2F1 antibody (Santa Cruz) 
before adding biotinylated survivin.   
 
Chromatin Immunoprecipitation (ChIP) 
HCT116 cells were seeded to 20% confluency in two 100mM plates. Twelve hours 
after seeding, culture media was supplemented with 2uM decitabine or vehicle (1:10,000 
diluted DMSO) and maintained for 4 days. Media was changed daily with fresh drug 
application. ChIP was carried out according to the IMPRINT ChIP kit protocol (Sigma). 
Briefly, cells were washed with 1XPBS, protein was crosslinked to DNA with formaldehyde 
Figure 12: Gel-shift methylation and labeling controls 
To confirm that the SssI reaction methylated the probe (a.) Unmethylated (U- lanes 1 
and 2) and methylated (M- lanes 3 and 4) probes were incubated with or without the 
methylation sensitive enzyme HinPI. To confirm equivalent labeling of the probes (b.) 
a dot blot was conducted comparing U and M probes to control oligos of known biotin 
label percentages.    
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for 10 min., and the reaction was quenched with glycine for 5min. Cells were washed with 
ice-cold PBS, scraped and resuspended in nuclei releasing buffer followed by sonication 
buffer. Lysates were sonicated in a Sonics Vibra Cell Ultrasonic Processor  at 40% output 
for 7 cycles of 30 second pulses (on ice) followed by 30 second rests on ice. An aliquot of 
sheared chromatin was reverse crosslinked, purified and fragments analyzed on a 1% 
agarose gel stained with ethidium bromide. The resulting DNA smear ranged from 1.5kB to 
200bp with the average size around 600-700bp. 
 
 Lysates were incubated in stripwells coated with anti-p53 or anti-IgG antibodies, 
washed, reverse crosslinked and purified. The pulled-down DNA was then amplified with a 
WGA whole genome amplification kit (Sigma) and subject to 35 cycles of PCR 
amplification with survivin promoter specific PCR primers. Fifty ng of input DNA 5 ng 
(10%) input and 50ng of ChIP’ed DNA were incubated in a 25uL reaction with 1X 
JumpStart PCR buffer (Invitrogen), 5mM MgCl2, 100nM primers, 200µM dNTPs and 0.25U 
JumpStart Taq (Invitrogen). Taq was activated for 5min. at 95º, reactions cycled at 95º for 
30sec. 60º for 30sec., 72º for 30sec. followed by a 10min 72º extension then kept at -20º 
until loading in a 5% 1X TBE polyacrylamide gel. Electrophoresis was performed and 
products visualized by ethidium bromide staining. The image was captured with a digital 
camera and band densities quantified using AlphaEase Digidoc software. Band densities 
from the experimental samples were normalized to input band densities.   
 
Statistical Analysis 
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Differences for QPCR decitabine studies were calculated by a two-way ANOVA 
followed by Tukey’s ad hoc test.  
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Results 
 
Demethylation of the survivin promoter results in p53-dendent survivin repression 
To determine if survivin promoter methylation regulates gene expression, cells were 
treated with the demethylation agent 5-aza-2-deoxy-cytidine (decitabine) for four days to 
demethylate the survivin promoter. Decitabine is a nucleoside analogue. It resembles 
cytidine however, it is modified such that the carbon in the #5 position in the nucleoside 
which is the site of methylation is replaced with nitrogen (5-aza) which can not be 
methylated (Figure 13, downloaded from wikipedia) . The 5-aza-2-deoxy-cytidine gets 
incorporated into DNA in place of cytidine during replication therefore demethylating the 
genome. Also, the presence of the excess nucleoside attracts and binds to the DNA 
methyltransferase enzymes, thus acting as a DNA methyltransferase inhibitor, and further 
decreases the methylation of DNA.   
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Structures of Cytidine and Decitabine 
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MSP analysis indicated that the survivin promoter in both the HCT116 wild type and 
p53 null cell lines was methylated but was unmethylated in Ishikawa cells (Figure 14). Four 
day decitabine treatment markedly (but not completely) reduced methylation of the survivin 
promoter in the HCT116 cells (Figure 15a). Immunoblot and/or QPCR analysis showed that 
survivin was significantly repressed following decitabine treatment in the wild-type cells 
(67%, p=0.05) but not in the p53 null cells (27%, non-significant) nor in the Ishikawa cells 
(10% at 1µM, no change at 2.5µM) (Figure 15b and 15c). The c-Myc gene is another 
oncogene which has been shown by others to be repressed by decitabine treatment in a p53 
independent manner and was measured as a control for drug induction. We found that in 
both wild-type and p53-null HCT116 cells as well as in Ishikawa cells c-Myc was strongly 
repressed following decitabine treatment. These results show that survivin expression is 
regulated by DNA methylation because decitabine treatment repressed survivin in HCT116 
cells that contain a methylated promoter but not in Ishikawa cells that contain an 
unmethylated promoter. Also, this repression is dependent on the presence of p53 because 
the p53-null HCT116 cells that also contain a methylated survivin promoter were not 
repressed by drug treatment.  
 
 
 
 
 
 
 
 
Figure 14: MSP analysis of the survivin promoter in cell lines 
Bisulfite treated DNA from HCT116 cells and Ishikawa cells were incubated 
with MSP primers for methylated (M) or unmethylated (U) survivin DNA as 
described in Chapter 2. Water and SssI methylated DNA samples were included 
as negative and positive controls respectively. 
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Figure 15: Survivin is repressed by decitabine in a p53 dependent manner 
HCT116 and/or Ishikawa cells were treated with decitabine for 4 days then harvested for 
analysis. (a.) genomic DNA was isolated, bisulfite treated and incubated with MSP 
primers for methylated (M) or unmethylated (U) survivin DNA. (b.) Immunoblot 
analysis of isolated protein from all three cell lines. B-actin serves as a loading control, 
c-Myc is a biological control for drug induction. Band densities for survivin in the 
Ishikawa cells were caculated and normalized to B-actin band densities: C=0.57, 
1µM=0.51 and 2.5µM=0.57 in relative units (c.) QPCR analysis of RNA isolated from 
HCT116 cells. p<0.05 by ANOVA followed by Tukey’s ad hoc test 
  Modified from Nabilsi et al Oncogene 2009 
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Survivin repression by decitabine is not due to off-target high dose treatment 
It has been observed that high dose decitabine treatment often causes non-specific 
off-target effects. To confirm that the survivin repression we observed was not due to off-
target effects of high dose (2µM) drug treatment, we repeated the experiment with a low 
dose 200nM decitabine treatment. We again observed by QPCR significant survivin 
repression in the decitabine treated wild-type cells (58% repression, p<0.05) but not the p53-
null cells (21%, non-significant) (Figure 16a). QPCR analysis of c-Myc gene expression 
served as a control for drug induction and we observed significant repression of c-Myc 
following decitabine treatment in both cell lines (Figure 16b). We concluded that the 
repression of survivin was not due to off-target high dose treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Low dose decitabine treatment of HCT116 cells 
QPCR analysis of RNA isolated from HCT116 cells following 4 day treatment with 
low dose 200nM decitabine. (a.) Survivin levels and (b.) c-Myc levels are normalized 
to 18s. *p<0.05 by ANOVA followed by Tukey’s ad hoc test. 
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Survivin repression by decitabine is not due to non-specific cell cycle effects 
 One important consideration in comparing the effects of decitabine on survivin 
expression in the wild-type and p53-null cells is the effect of decitabine on the cell cycle. 
Survivin expression is cell cycle regulated, increasing during G2 and M phases of the cell 
cycle. If the wild-type cells arrest in G1 whereas the p53-null cells arrest in G2 in response 
to drug treatment then this variation in cell cycle arrest could explain the observed survivin 
repression in wild-type cells but not p53-null cells.  
 
 
 
 
 
 
 
 
 
 
 
 
To determine if survivin repression by decitabine is due to non-specific cell cycle 
effects, wild-type and p53-null HCT116 cells were treated with decitabine or vehicle for 
four days and then harvested for cell cycle analysis by propidium iodide staining. The 
mechanism of decitabine action suggested that the drug would cause both cell lines to arrest 
 
Figure 17: Cell cycle profile of decitabine treated HCT116 cells 
Propidium iodide staining of HCT116 cells treated with decitabine (Dec) or vehicle 
indicated the DNA content and thus (a.) the percentage of cells in each stage of the 
cell cycle. (b.) Ratio of cells in the G2/M phase of the cell cycle.  
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in S-phase however cell cycle analysis indicated that both wild-type and p53-null cells 
mildly arrested in G1 phase (Figure 17a). To determine if there were any cell cycle changes 
that would variably affect survivin expression, we calculated the ratio of cells that were in 
G2/M-phase before and after treatment in both cell lines and determined that there was no 
difference in the G2/M phase fraction in the wild-type cells compared to the p53-null cells 
following decitabine treatment (mean ratio wt=0.31, wt + decitabine=0.31, p53-null=0.32, 
p53-null + decitabine=0.32; p=0.98 by ANOVA) (Figure 17b). We concluded that survivin 
repression by decitabine was not due to non-specific cell cycle effects. 
 
Survivin repression by decitabine is not due to non-specific alterations in proliferation 
index 
 Survivin expression in many cases is associated with the proliferation index of the 
cell or tissue type in which it is measured and decitabine treatment often causes cells to slow 
or stop proliferating. Therefore it is important to determine if the observed repression of 
survivin in wild-type cells but not p53-null cells is due to a non-specific alteration of the 
proliferation status of the wild-type cells but not the p53-null cells in response to drug 
treatment. To determine the proliferation status of the cells, we measured the levels of Ki67, 
a nuclear antigen commonly used as a marker of proliferation, by QPCR. We found that 
there was a non-significant decrease in Ki67 transcript levels following drug treatment, 
however the decrease was similar in both cell lines (wt= 29% decrease, p53-null= 27% 
decrease) (Figure 18a) and could therefore not account for the 62% decrease in survivin 
levels in the wild-type cells compared to the 27% decrease in survivin levels in the p53-null 
cells (Figure 15c). Interestingly, the change in survivin and Ki67 levels was equal (27%) in 
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the p53-null cells suggesting that the observed small survivin repression in the p53-null cells 
was due to decreased cellular proliferation. To normalize for this proliferation effect, we 
calculated the ratio of survivin/Ki67 for each sample and found that normalizing for non-
specific proliferation effects greatly augmented the observed p53 dependent survivin 
repression in response to decitabine treatment (Figure 18b). We concluded that the 
repression of survivin by decitabine in the wild-type cells was not due to a non-specific 
proliferation effect.           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18: Proliferation index of HCT116 cells following decitabine treatment 
QPCR analysis of RNA isolated from HCT116 cells following 4 day treatment 
with low dose 200nM decitabine. (a.) Ki67 levels are normalized to 18s (b.) 
survivin levels are normalized to Ki67. ***p<0.0005 by ANOVA followed by 
Tukey’s ad hoc test. 
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Methylation of the survivin p53/E2F binding site inhibits p53 binding but not E2F1 
binding in vitro 
We have shown that demethylation of the survivin promoter results in survivin 
repression through a p53 dependent mechanism. Next we explored whether the methylation 
state of the survivin promoter could affect the DNA binding ability of p53. Methylated and 
unmethylated double stranded oligonucleotide probes representing the p53/E2F binding site 
sequence from the survivin promoter were end labeled for gel shift analysis. We observed a 
strong gel shift in the presence of purified human p53 protein with the unmethylated probe 
but a greatly diminished shift with the methylated probe (Figure 19a) indicating that p53 
binding to the survivin promoter was reduced by DNA methylation. Pre-incubation with an 
anti-p53 antibody resulted in complete elimination of the gel shift signal indicating a 
specific interaction between the probe and p53.  
 
 
 
 
 
 
 
 
 
 
Figure 19: Gel-shift analysis of the survivin p53/E2F binding site 
Gel shift assay of biotin labeled methylated or unmethylated probe incubated with (a.) 
purified p53 protein or (b.) E2F1 enriched nuclear lysates. Antibodies to p53 and E2F1 and 
unlabeled probe serve as controls for the specificity of the reactions. 
 
 Modified from Nabilsi et al Oncogene 2009 
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The transcription factor E2F1 is an activator of survivin and its binding site overlaps 
the p53 binding site in the survivin promoter. To determine if methylation specifically 
inhibits p53 binding or if E2F1 binding would be similarly affected, we incubated nuclear 
lysates enriched with E2F1 protein with the methylated and unmethylated probes. We 
observed that E2F1 binding resulted in an equal gel shift for both probes and was therefore 
not affected by methylation (Figure 19b). Pre-incubation with an anti-E2F1 antibody 
resulted in a diminished gel shift signal and the presence of a supershift indicating a specific 
interaction between the probe and E2F1. We concluded that DNA methylation can 
specifically inhibit the binding of p53 to the p53 binding site in the survivin promoter.  
 
Demethylation of the survivin promoter increases p53 binding in HCT116 cells  
 To determine if DNA methylation affects p53 binding to the endogenous survivin 
promoter, we treated HCT116 wild-type cells with decitabine as described above to 
demethylate the survivin promoter and conducted chromatin immunoprecipitation (ChIP) 
analysis. Sheared chromatin from drug or vehicle treated cells was incubated with an anti 
p53-antibody to pull down DNA bound by p53. The DNA was purified and PCR amplified 
with survivin specific primers to determine the relative occupancy of p53 on the methylated 
(vehicle treated) vs. unmethylated (decitabine treated) survivin promoter. Anti-IgG 
antibodies were used in a parallel reaction to control for non-specific DNA pull-down. We 
observed a bright PCR product indicating enrichment of p53 occupancy on the survivin 
promoter following decitabine treatment compared to control and there was no band in the 
IgG negative control lane (Figure 20a). We quantified the band densities of PCR product 
from the pull down reactions by densitometry and normalized against the PCR products 
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from the input and observed a 4-fold increase in signal from the decitabine treated cells 
compared to control (Figure 20b). These results show that methylation can inhibit p53 
binding to the endogenous survivin promoter in cells.        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
We have shown that survivin expression is regulated by DNA methylation and that 
demethylation of the survivin promoter by decitabine results in specific survivin transcript 
and protein repression through a p53 dependant mechanism. These results are significant 
because DNA methylation is understood to silence, not activate gene expression. This is 
largely because gene regulation by DNA methylation is considered to be an “all-or-none” 
Figure 20: Chromatin immunoprecipitation analysis of the survivin promoter 
Wild-type HCT116 cells treated with decitabine or vehicle for 4 days were harvested for 
ChIP analysis with anti-p53 and anti-IgG antibodies. Immunoprecipitated DNA was 
amplified with survivin specific PCR primers and (a.) PCR products were analyzed by 
PAGE. (b.) Band densities were quantified by densitometry.  
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phenomenon whereby a gene is either silent or expressed and the silence is associated with 
nearly 100% promoter methylation. However physiologically, promoter methylation occurs 
at varying dosages not just 0% or 100%, indicating that there may be more to gene 
regulation by promoter methylation than just on-or-off. While the survivin promoter in 
human endometrial tumors was significantly hypermethylated compared to normal tissue, 
we never observed anywhere near 100% methylation of the survivin promoter in any of the 
tumors or cell lines, however with increasing methylation we observed increased survivin 
expression. Our results suggest that “low dose” promoter methylation may modulate gene 
expression and it is not necessarily an “all-or-none” event, nor is it restricted to gene 
silencing. While 100% promoter methylation will likely inhibit the basal transcriptional 
machinery from binding, lower doses of methylation may not be sufficient to interfere with 
the binding of such a large complex but it can interfere with other transcriptional regulators, 
including transcriptional repressors (which would result in gene activation).  
 
We explored the mechanism of increased survivin expression by promoter 
methylation and found by gel shift and ChIP that p53 binding to the survivin promoter is 
specifically inhibited by DNA methylation.  While there are several reports indicating that a 
link exists between p53 and DNA methylation (p53 represses DNMT1 (DNA methyl-
transferase 1) expression and can scaffold DNMT1 protein binding to promoters), to our 
knowledge we are the first to report that DNA methylation can inhibit p53 from binding to a 
target gene’s promoter. It is tempting to speculate that an auto-inhibitory mechanism exists 
whereby p53 binds to its target gene’s promoter and recruits DNMT1 to reversibly 
methylate the promoter thus inhibiting its own future binding until either a de-methylation 
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signal is initiated or until it represses DNMT1 expression to the point that promoter 
methylation can not be maintained. Since aberrant DNMT1 overexpression is often observed 
in tumors, this DNMT1-p53 interaction may be augmented causing hypermethylation at p53 
binding sites thus leading to aberrant inhibition of p53 binding and action. In the next 
chapter we will further explore the relationship between promoter de-methylation and gene 
expression. 
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CHAPTER 5: MICROARRAY ANALYSIS IDENTIFIES SEVERAL GENES THAT 
ARE REPRESSED BY DECITABINE TREATMENT 
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Introduction 
 One experiment that is commonly used to determine if a candidate gene is regulated 
by DNA methylation is to treat cells with decitabine and observe the effect on the expression 
levels of the gene in question. Since these studies are often conducted under the assumption 
that methylation only silences gene expression, data analysis is focused on genes that are 
activated by decitabine treatment, not genes which are repressed. We have reported data that 
shows activation of survivin expression by promoter methylation. Next we wanted to 
determine if there are other genes that are also activated by DNA methylation. We therefore 
treated Ishikawa and HCT116 cells with decitabine then conducted microarray analysis to 
measure changes in gene expression but focused our attention on genes that are repressed, 
not activated by decitabine treatment. In this chapter we will report genes that are repressed 
by decitabine in Ishikawa cells, and genes that are repressed in HCT116 cells in a p53-
dependent manner.   
 
Materials and Methods 
 
Microarray Analysis Using BeadChip Arrays 
Microarray experiments were conducted on two independent RNA samples from 
HCT116 cells and Ishikawa cells. RNA was isolated as described above and microarray
 
analysis was conducted using HumanRef-8 BeadChip arrays from Illumina. RNA was 
amplified and
 
hybridized according to the manufacturer’s protocol. Briefly, RNA is 
amplified and then cDNA synthesized via reverse transcription.  The cDNA is converted to 
cRNA containing biotinylated UTPs and then incubated with avidin labeled Cy3 dye.  Each 
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sample was then added to a separate array on the bead chip and incubated in a warm 
rotisserie overnight.  Next day, bead chips are washed and scanned. Following scanning, 
Bead Studio 3 (Illumina) software was used for data analysis. Bioinformatic pathway 
analysis was conducted utilizing Ingenuity software. 
 
QPCR analysis was conducted to validate microarray results. Assays were conducted 
as described in chapter 2 with the exception that UPL (universal probe library) probes were 
used in place of Taqman probes and analyses were conducted using the ddCT method (as 
described for the CNV assay in chapter 2) without a standard curve.  
 
 
Statistical Analysis 
Differences for QPCR validation of microarray results were calculated by unpaired t-
tests. Differences were considered significant if p<0.05. For microarray analysis, after 
background subtraction arrays were normalized to each other by quantile normalization.  
Changes in gene expression were tested using a modified t-test that employs estimates of 
variation that include sequence specific biological variation (sbio), nonspecific biological 
variation (sneg) and technical error (stech) ( Illumina User Guide, rev B. page 6-11 – 6-12, 
2005, Illumina Inc) . Genes were considered differentially regulated at p<0.001. 
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Results 
 
Microarray analysis identifies genes that are repressed by decitabine in Ishikawa cells 
 Expression analysis of RNA isolated from Ishikawa cells grown in 2uM decitabine 
for 4 days (all in duplicate) showed that of the 22,000 transcripts present on the chip, after 
quantile normalization, 2,752 were changed with a p-value ≤ 0.001. Scatter plot analysis 
indicates that of the 2,752 changed genes, 1,261 genes showed increased expression 
indicating activation by demethylation (the traditional view of decitabine action) and 1,429 
genes showed decreased expression indicating repression by demethylation (Figure 21c). 
The scatter plot analysis also shows that the gene expression signatures of the biological 
duplicates for control and drug treated cells were incredibly similar with r
2
 values of 0.99 
and 0.98 respectively indicating positive quality control (Figure 21a. and b.). 
 
Bioinformatic pathway analysis of the results indicated that several of the repressed 
genes are involved in cell cycle regulation and are targets of p53 (Table 2) indicating that 
this mechanism of repression by demethylation occurs in genes other than survivin and in a 
different cell-type. Notably, survivin expression was not changed following decitabine 
treatment in these cells consistent with our findings that the survivin promoter is 
unmethylated in Ishikawa cells and that survivin protein levels were not changed in these 
cells following drug treatment (Chapter 4). However, c-Myc levels were reduced by 51% 
again consistent with the immunoblot data we showed previously.   
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Figure 21: Microarray scatterplots of decitabine treated Ishikawa cells 
(a.) Comparison of two control cell samples, r
2
=0.99 and (b.) Comparison of 
two drug treated samples, r
2
=0.98 indicating similar gene expression 
signatures of the biological controls. Blue marks indicate significantly 
expressed genes (c.) Comparison of control vs. drug treated, r
2
=0.88 with 
gene changes of p<0.001 indicated in blue, red lines indicate the 2-fold 
change boundaries. 
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Microarray analysis identifies 42 genes which are repressed by decitabine in a p53 
dependant manner  
To determine if other genes are de-repressed by DNA methylation by a p53 mediated 
mechanism, we obtained RNA from HCT116 wild type and p53-null cells treated with 
decitabine or vehicle (all in duplicate) then analyzed gene expression by microarray. We 
observed that 325 genes were repressed more than 2-fold (3,056 total), p<0.001 by drug 
 Control Decitabine p-value 
MYC 1263.1 670.9 6.87E-20 
HK2 460.4 217.5 3.21E-19 
CCNA2 2102 1148.9 6.83E-12 
MAD2L1 2282 1474.5 1.02E-10 
BAX 139.2 66.1 4.71E-09 
DUT 926.6 578.9 5.76E-09 
UBE2C 153.8 74.7 5.94E-09 
CDC25C 385.5 247.7 1.06E-08 
TMEM97 3900 2190.3 7.12E-08 
CRIP2 1939.3 1361 2.20E-07 
PSRC1 952.4 700.4 4.96E-07 
RFC3 77 23 1.11E-06 
CDK4 3783 2455 1.13E-06 
PBK 1169.6 711.9 1.71E-06 
CENPF 1144.4 718.5 3.18E-06 
CCNG1 1802.1 1046.9 3.54E-06 
TOP2A 3395.1 2659.6 4.14E-05 
BUB1B 1027.3 796.2 4.57E-05 
AURKB 1196.5 767.4 1.71E-04 
PODXL 171.7 83.9 2.72E-04 
RAC1 398.1 276.4 8.60E-04 
 
Table 2: p53 regulated genes repressed by decitabine treatment in 
Ishikawa cells 
Gene symbols, signal and p-values are indicated for control and drug treated 
cells ascending by p-value. Genes in bold are implicated in cell cycle control. 
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treatment in the wild type cells and 251 genes were repressed more than 2-fold (2,559 total), 
p<0.001 in the p53 null cells. To confirm that the drug treatment reproduced results reported 
by others, we examined the expression status of 5 genes (NKX2-5, SPOCK2, SLC16A12, 
DPY5, and GALR2) reported to be epigenetic biomarkers of colon cancer in human tumors 
and that are re-expressed following decitabine treatment in colon cancer cell lines (16). We 
found that 3 of the 5 genes (NKX2, SPOCK2, and GALR2) were re-expressed following 
decitabine treatment in both cell lines whereas the other 2 did not change. Since GALR2 is 
the most predictive of the 5 genes (85% sensitivity, 95% specificity for predicting colon 
cancer), we were confident that decitabine treatment was successfully administered in these 
cells.  
We ranked the genes repressed in the wild type cells by p-value then compared those 
numbers to the p-values of the same genes in the p53 null cells. We identified 50 genes 
which exhibited a statistically significant repression following decitabine treatment in the 
wild-type cells but a non-significant (or less significant) change in the p53-null cells. 
Subsequent analysis indicated that 46 out of the 50 identified genes (92%) contained 
canonical CpG islands in their promoters and/or within their first 2 exons. These 46 genes 
are listed in Table 3. Notably, the majority of these genes are associated with cancer 
progression and/or cell proliferation.  
 
We selected a subset of genes: HMGB1, UNC84b, Nek2, CDC25C and CCNF for 
further validation. QPCR analysis was conducted on an independent set of control and 
treated cells from both cell lines. Validation studies indicated that HMGB1, Nek2 and 
CDC25C all exhibited statistically significant, p53 dependent, gene repression by decitabine 
72 
treatment (HMGB1 mean wt repression = 65%, mean p53null repression = 30%, p=0.042; 
Nek2 wt = 68%, p53null= 10%, p=0.0088; CDC25C wt = 89%, p53null = 59%, p=0.0099) 
(Figure 22). QPCR analysis indicated that UNC84b and CCNF were also repressed by 
decitabine treatment, however by QPCR, this repression was not dependent on p53 (data not 
shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Validation studies of microarray results 
QPCR assays for (a.) Nek2 (b.) HMGB1 and (c.) CDC25C were designed and 
transcripts measured in RNA isolated from an independent treatment experiment. 
Data were quantified using the ddCT method and are presented as %repression 
compared to control for each cell type. *p<0.05, **p<0.005, unpaired t-test, n=3. 
                           Data in Nabilsi et al, Oncogene 2009   
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Symbol wt wt+dec p-value p53null p53null+dec p-value 
Cell cycle      
NEK2 488.4 243.8 7.36E-38 480.9 462.3 1.65E-01 
AMH 86.9 39.6 1.77E-05 101.8 76 3.15E-01 
HD 65.1 27.4 8.67E-04 93.1 55.2 5.30E-01 
GLI2 90.2 43.4 2.36E-05 91.2 58.4 1.05E-03 
NEDD4L 174.3 69.6 6.52E-18 161.1 111.8 1.15E-03 
NUMA1 71.1 33.8 5.75E-04 72.6 38.5 2.39E-03 
UNC84B 185.6 86.1 6.06E-16 140.1 140.1 4.80E-03 
TNKS1BP1 152.4 72.4 4.74E-08 163.3 125.1 1.46E-01 
FAM29A 92.3 39.9 1.75E-04 101.8 60.2 1.64E-02 
CCDC18 126.3 55.6 1.52E-06 124.9 87.8 7.87E-03 
CDC25C 331.2 158 3.89E-32 341 241 4.97E-09 
CENPF 1066.4 441.8 6.26E-27 1152.7 600.9 1.12E-14 
CEP110 161 63 5.99E-10 123.8 81.8 3.01E-07 
CEP57 126.5 59 4.31E-09 93.9 70.5 3.49E-06 
CCNF 395 192.6 2.40E-37 339 319.1 6.20E-06 
Cell death      
HMGB1 339.3 168.6 7.44E-12 294.1 357.2 7.50E-01 
PTPN9 62.8 31.1 4.57E-04 66.3 45.1 1.29E-02 
NRTN 81.2 36.4 4.40E-05 82.2 52.9 3.58E-03 
MYO18A 127.9 57.1 3.15E-04 128.9 85.5 9.24E-02 
RTN3 324.8 160.1 2.61E-13 338.5 243.1 2.46E-03 
BAG2 91.5 41.3 8.94E-04 91.2 68.5 1.45E-01 
Development      
CAPN5 74.7 23.1 4.00E-04 73.3 48.1 1.32E-01 
FZD7 93 43.5 8.20E-06 67.5 65.4 4.53E-03 
BSN 51 9.4 9.38E-05 58.4 21.5 1.24E-03 
RAPGEFL1 84.9 35.5 1.25E-05 52.3 56 4.33E-02 
LMNB1 879.1 431 4.79E-04 803.6 443.1 1.38E-02 
NR2F1 755.9 282.2 7.36E-38 310.9 220.3 7.36E-38 
Cancer       
MSI1 71.1 18.9 2.61E-06 92.1 46.7 7.13E-02 
RPSA 255.1 115.7 1.11E-11 332.9 214 9.79E-02 
TMEM18 71.1 27.6 6.05E-05 89.2 32.8 6.39E-03 
MET 1442.9 541.2 7.36E-38 497.5 323.5 7.36E-38 
Nucleic Acid catabolism/metabolism    
OLA1 53.1 15.7 4.55E-04 55.8 35.2 3.68E-02 
ALDH6A1 290.8 142.1 1.91E-26 393.6 236 6.99E-03 
PABPC3 287.1 129 4.49E-27 299.1 247.5 1.26E-02 
DNA binding      
ENOX1 44.6 6.7 3.42E-04 47 15.2 1.39E-03 
ZC3H3 164.4 79 3.27E-06 189 105 1.08E-03 
NFIX 832.2 378.6 7.36E-38 499.4 401.5 7.36E-38 
Unknown/Miscellaneous     
SH3RF2 92.6 45.7 2.33E-05 156.1 105.5 2.26E-01 
NXPH4 72.1 35.3 3.83E-04 88.9 55 2.20E-01 
LZTFL1 214.2 100.2 4.15E-17 207.3 153.9 5.06E-02 
C4ORF29 67.7 29.4 4.05E-04 47.9 33.2 8.25E-03 
TBC1D17 91.1 42.8 4.15E-04 68.1 61.5 3.13E-02 
REEP3 61 18.2 7.11E-05 73.8 33.7 5.56E-03 
GPR162 89.4 38.5 1.35E-08 111.6 62.8 2.52E-03 
C3ORF62 65.1 20.9 9.50E-04 43.4 26.5 2.18E-03 
SAMD5 87.1 25.7 7.51E-08 60.4 50.1 1.01E-03 
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Discussion 
In this chapter we conducted microarray experiments and uncovered several genes 
that are repressed following decitabine treatment. Conducting these experiments in HCT116 
cells allowed us to uncover 46 genes that may be regulated by methylation through a p53-
dependent mechanism. Further studies of the methylation status of these candidate genes 
will be necessary to determine if they are truly repressed by demethylation. We concluded 
that gene de-repression by methylation may be a common mechanism of gene regulation 
that has been previously unrecognized. There were also several genes that were repressed by 
decitabine treatment in a p53 independent manner indicating that other transcriptional 
repressors may be regulated similarly.   
 
We also observed that an interesting set of genes that were completely unexpressed 
in the control cells then became highly expressed (up to 10,000-fold) following decitabine 
treatment in both HCT116 cell types. If we express the data as a scatter plot, we can see that 
these genes cause a “spur” on the left-hand side of the plots (Figure 23 a, green bracket). 
Many of these genes are members of a G-antigen protein family (GAGE). The GAGE 
family transcripts and proteins are cancer/testis specific antigens meaning they are highly 
Table 3: Genes repressed by decitabine in a p53 dependant manner 
This table lists genes that are significantly changed in the wild type cells but not 
in the p53 null cells. Genes are grouped by function from Ingenuity software 
analysis 
Nabilsi et al Oncogene 2009 
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expressed in primordial male germ cells during development and are often expressed in 
different types of cancers. Intriguingly, most of these testis-specific GAGE genes are located 
on the X-chromosome. The actual function of these proteins remains unknown however they 
are potent activators of T-cell responses and are currently being studied as targets for cancer 
immunotherapy. Their robust activation by decitabine in HCT116 cells suggests that they 
are silenced by methylation in this cell type. Perhaps coupling decitabine treatment with T-
cell based immunotherapy may enhance the efficacy of immune-based treatments in patients 
with lower GAGE presentation?  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Microarray scatter plots of decitabine treated HCT116 cells 
Data following quantile normalization from (a.) wild-type cells control vs. dec., n=2 
(b.) p53-null cells control vs. dec., n=2 and (c.) wild-type cells control vs. dec. Blue 
dotes represent genes changed by p<0.001, red lines indicate the 2-fold range 
boundaries and the green bracket highlights the “spur” of genes that are silent and 
become highly expressed following drug treatment  
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The scatter plots also suggest that more genes were changed following decitabine 
treatment in the p53-null cells than in the wild-type cells (Figure 23 a. vs. b.). This is 
actually due to high variability between decitabine wild-type replicates rather than a 
biological reality. One of the treated wild-type samples changed much more radically than 
its biological replicate thus confounding the statistics and dampening the statistical 
significance of the changes. If we remove this sample from the analysis and re-analyze the 
data with n=1 for this group, we observe very similar numbers for genes changed following 
treatment in the wild type cells and in the p53-null cells (Figure 23c). To maintain biological 
relevance, we conducted our analyses with the smaller set of genes from the n=2 sample set. 
This greatly diminishes the number of candidate genes that we have to work with however it 
also decreases the number of false positives and is therefore more likely to be biologically 
relevant.  
 
Finally, we compared the gene lists for expression changes of at least 2-fold 
repression with p<0.001 from all three cell types following decitabine treatment. We found 
that 525 genes are similarly repressed in the HCT116 cells but there are genes that change 
specifically for each cell type (300 in wild-type, 209 in p53-null), indicating that theses 
genes may also be regulated by p53 or they may have a different methylation status in each 
cell line (Figure 24). Two hundred and ninety-nine genes changed specifically in Ishikawa 
cells again suggesting that their methylation status in these cells differs from the HCT116 
cells. There are also 40 genes that are reliably repressed in all 3 cell types. These 40 genes 
that are common to all groups are listed in Table 4. These genes are either consistently 
methylated in all tested cell lines and are repressed by demethylation like survivin, or they 
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represent non-specific off-target effects of drug treatment that can not be attributed to their 
methylation status. Thirty-three of the 40 genes (83%) contain canonical CpG islands in or 
near their promoter regions. This enrichment of CpG islands suggests that they are likely 
exhibiting methylation-based repression rather than non-specific effects. Further studies 
exploring the methylation status of these candidate genes will be necessary to determine 
whether their repression by decitabine treatment is due to regulation by DNA methylation.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24: Venn diagram of microarray results 
Comparison of genes that were repressed more than 2-fold by decitabine 
treatment. Overlaps indicate shared genes for the indicated cell type. 
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Gene 
Island size 
(bp) Ratio Location   
ACOX2      
ACSM3      
ACY1L2 893 0.93 promoter   
ALDH3A2 1139 0.75 promoter   
ARHGAP18      
C14orf93 222 1.06 promoter   
 505 1.02 intron 1   
DDIT4 1531 0.75 
promoter-
exon3   
ESPN 824 1.03 
promoter, 5 more islands 
throughout  
EVA1      
FABP6      
FECH 549 0.94 promoter   
GALNTL4 1698 0.81 promoter   
GBAS 857 1.02 promoter   
HNRPDL 2406 0.93 promoter-intron1  
LHPP 497 1.05 promoter, 2 more throughout 
LRRC20 1077 0.84 promoter   
LRRC45 1349 0.79 promoter, 3 more throughout 
MRPL11      
MYB 2257 0.95 promoter-intron1  
NFIA 811 1.12 promoter   
NIBP 299 0.79 promoter, 5 more throughout 
NICN1 365 0.85 promoter   
NSBP1      
NTHL1 900 0.9 promoter-intron1  
OSGEPL1      
PFKFB4 831 0.66 promoter   
PPA2 771 0.87 promoter   
RAMP1 758 0.99 promoter-intron1  
SCD 1540 0.82 promoter-intron1  
SCNN1A 662 0.74 exon2   
SLC16A14 1082 0.79 promoter-intron1  
SLC29A2 923 0.8 
promoter-
exon2   
SREBF1 1063 0.91 promoter-intron1, 2more throughout 
SRI 591 0.86 promoter-intron1  
THNSL1 706 0.86 promoter-intron1  
TJP3 354 0.77 exon4   
 259 0.91 exon18   
TLOC1 612 0.88 promoter-intron1  
WDR4 697 0.93 promoter   
YEATS4 643 1.01 promoter-intron1  
ZNF695 566 0.78 promoter-intron1  
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Table 4: Genes repressed at least 2-fold in all cell types 
Gene symbols for 40 genes repressed by decitabine in all cell types are listed 
along with the size of their corresponding CpG islands, the ratio of 
observed/expected CpGs (must be greater than 0.6 to be considered an island) 
and the location of the island on the gene. Blank CpG island information 
indicates lack of a CpG island for that gene. 
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Summary and Significance 
  
Over the past 2 decades there has been an exponential increase in the study of DNA 
methylation and its effects on human disease, especially cancer. Many dogmatic tenants 
have been challenged, such as the ideas that DNA methylation is irreversible and only 
functions to silence gene expression (19, 97). There are however many basic questions that 
have remained unanswered. What is the function of DNA methylation? What is the signal 
that marks a DNA sequence for methylation? What comes first, the silencing or the 
methylation? To begin to answer these questions we need to more fully understand the effect 
of DNA methylation on gene expression and the nuances of the interactions between 
methylated DNA and transcription factors.  
  
Traditionally DNA methylation in mammals has been associated with gene silencing. 
This is because early studies of DNA methylation were focused on development and DNA 
methylation is the major mechanism for silencing gene expression during developmental 
imprinting and for X-chromosome inactivation in females (70, 95, 96, 107). More recently 
however, large scale genome-wide studies of DNA methylation patterns indicate that DNA 
methylation occurs more frequently on genes that are actively transcribed, in intergenic 
regions more than promoter regions (46), and that the active X-chromosome is more heavily 
methylated than the inactive X-chromosome (41). Furthermore, genome wide ChIP studies 
indicated that the methyl binding protein MeCP2 was more commonly found bound to genes 
which were actively transcribed than genes that were silenced (116). These results indicate 
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that we are just at the beginning of understanding the role of DNA methylation in regulating 
gene expression.   
  
Our studies have uncovered two novel findings for epigenetic regulation by DNA 
methylation. One is that DNA methylation can activate gene expression of the oncogene 
survivin. The other is that the transcription factor p53 can be inhibited from binding to 
methylated DNA. We have shown that in a human disease, endometrial cancer, DNA 
methylation at a specific regulatory region of the survivin promoter (the p53 binding site) 
correlates with increased survivin expression. We have also shown that manipulation of the 
methylation status of the survivin promoter alters its gene expression and the ability of p53 
to bind to the promoter. These results are important because they challenge the current 
understanding that DNA methylation only silences gene expression and that only the 
binding of methyl binding proteins are affected by DNA methylation. Furthermore, through 
microarray studies we have identified 46 candidate genes which may be similarly regulated 
indicating that this is an underappreciated mechanism of epigenetic regulation.    
 
Clinically this project is significant because it may result in unveiling novel targets 
for epigenetically based cancer therapeutics.  There may be undiscovered methyl binding 
factors involved in gene activation as opposed to gene silencing which could be targeted by 
pharmacologic inhibitors. Alternatively, decitabine is currently used mainly to treat 
leukemia. It is possible that this drug may be useful in treating solid tumors which retain 
wild type p53 expression. De-methylation could allow p53 to re-establish its function as a 
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tumor suppressor in these tumors. Our study would serve as a proof of principle to begin 
using decitabine to treat patients with these types of tumors. 
 
Future Directions & References 
 
There are several exciting directions that can be taken to further explore the novel 
findings uncovered in our study. Each candidate gene identified by microarray can be 
validated as a novel target of epigenetic and/or p53 regulation. We are currently conducting 
these types of studies on the mitotic kinase Nek2 which is an exciting target because it is 
overexpressed in several tumor types and is a biomarker of poor prognosis in breast cancer.  
 
It would also be interesting to explore more fully the effect of DNA methylation on 
transcription factor binding. We showed by ChIP that if we de-methylate the survivin 
promoter by treating with decitabine that there is increased binding of p53 to the survivin 
promoter. We could expand this analysis by applying the DNA pulled-down by p53 (in pre 
and post treatment samples) to a Promoter Chip and look for genome wide promoter 
changes in p53 binding patterns in response to decitabine. This can then be expanded to 
include other transcription factors and we could then comprehensively describe the 
promoters and transcription factors that are affected by DNA methylation. This would not 
only expand our knowledge about the interaction between transcription factors and DNA 
methylation but may also help us uncover the true physiological function of DNA 
methylation by indicating the promoters and transcription factors with which it specifically 
interacts. 
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I would also be interested in determining which methyl binding proteins are recruited 
to the methylated survivin promoter and to determine if binding of these specific proteins is 
associated with gene activation as opposed to gene silencing. I would start with MeCP2, 
which has already been shown to preferentially bind to active genes in neuronal cells. If so, 
pharmacologic inhibitors of these methyl binding proteins may be developed as novel 
epigenetic cancer therapeutics. Along the same line of inquiry, I would like to determine 
how the histone modification signature surrounding the methylated survivin promoter 
compares to the histone signature of the unmethylated survivin promoter. There may be a 
novel histone marker for methylation activated genes compared to methylation silenced 
genes which could then be targeted with the many histone modification-based cancer 
therapies.  
 
Our study could also lead to translational applications. We are currently 
collaborating with Dr. Peter Laird, the director of the Epigenome Center in California to 
explore bioinformatically if the genes which were identified as repressed by decitabine 
treatment in our microarray are commonly found to be methylated in their database of 
genome-wide methylation patterns in human tumors. If so, they would represent more cases 
of gene activation by DNA methylation and may persuade more laboratories to explore this 
possibility in their studies. They may also represent important targets for methylation based 
cancer therapy and may enhance the case for using agents like decitabine to treat solid 
tumors.  
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An alternate route to translating this work clinically would be to determine if this 
regulation of survivin by DNA methylation is tissue specific or if it also occurs in gliomas. 
There is a laboratory in Chicago, IL that has designed a viral therapy for malignant glioma 
whereby the survivin promoter drives the expression of an oncolytic virus (101, 102). If 
DNA methylation increases survivin expression in gliomas then they may be able to enhance 
the expression of their virus by simply methylating the survivin promoter in vitro prior to 
treatment.  
 
 In conclusion, I believe that we have made a strong case for the possibility that gene 
regulation by DNA methylation is more sophisticated than just an “on-off” phenomenon and 
that gene activation by DNA methylation may have biological consequences, including 
cancer progression. There may be more subtle changes in gene expression that are directed 
by or result from DNA methylation. Perhaps we should move away from the “on-off” toggle 
switch mentality and begin examining DNA methylation as a dial dimming/brightening 
switch?  
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